

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
100999	Yilin	Yang	United States	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 01	Nogo-B Deletion Alleviates Alcohol-induced Liver Injury by Anti-inflammatory Macrophage Polarization
101014	Yanfei	Lang	China	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 01	Akr1B8 Deficiency Prevents the Progression of Alcoholic Liver Disease in Mouse Model
101221	Chih-Wen	Lin	Taiwan	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 01	Aldh2 Rs671 Polymorphism Predicts Clinical Prognosis of Alcohol Related HCC after Hepatectomy
101276	Yue	Chen	China	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 01	Jphx formula Treated Acute Ald in Mice by Regulating the Metabolism of Bile Acids Via Gut-Liver Axis
101383	Chao	Xie	China	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 01	Tfr2 PA75V Mutation Aggravates Liver Iron Overload in Alcoholic Liver Disease Via Erk Pathway
101874	George	Lau	Hong Kong	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 01	Impact of Alcoholic Cirrhosis on Development of Renal insufficiency Post-Liver Transplantation
100327	Sawan	Bopanna	India	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 02	Alcohol Consumption Patterns Among Various Presentations of Alcoholic Liver Disease in South Asians
100490	Mikaela	Daniells	Australia	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 02	Addressing Arld and Aud with An innovative Hepatology Nurse-Led Alcohol Reduction Program
100710	Yang Hyun	Baek	South Korea	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 02	Alcohol Consumption and the Risk of Liver Disease: A Nationwide, Population-Based Study
100869	Vicki Wing-Ki	Hui	Hong Kong	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 02	Secular Trend of Disease Burden of Alcoholic Hepatitis in Regionendemic with Chronic Viral Hepatitis
101541	Jeong-Ju	Yoo	South Korea	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 02	Incidence, and Outcomes of Alcohol Related Liver Diseases in Korea: Nationwide Analysis
101542	Jeong-Ju	Yoo	South Korea	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 03	Impact of Smoking on Alcoholic Liver Disease and Mortality: Compounding Hazards
101576	Ping	Zhu	China	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 03	Neutrophil-to-Lymphocyte Ratio and Infection in Patients with Severe Alcoholic Hepatitis
101962	Ramalah	Ramalah	Indonesia	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 03	Genetic Analysis of the Composition of Fatty Acid in Diagnosis and Therapy of Alcoholic Liverdisease
102012	Manasa	Alla	India	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 03	Hyperimmune Bovine Colostrum is Safe and Effective in Steroid ineligible Severe Acif- Ah Patients
200077	George	Lau	Hong Kong	Oral	March	28	Thursday	PM	Alcohol Related Liver Disease 03	Effect of Leucogen in Treating Alcoholic Liver Cirrhosis with Thrombocytopenia or Leukopenia
100040	Mengyi	Shen	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 01	Metabolic Reprogramming of Cd4+ T Cells by Msc-Evs Attenuates Aih Through Mitochondrial Transfer
100367	Hongcui	Cao	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 01	Msc-Derived Exosomes Attenuate Hepatic Fibrosis in Psc Through Inhibition of Th17 Differentiation
100368	Hongcui	Cao	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 01	Ros-Responsive Nanoparticle Delivery of Oca Mitigate Mitochondrial Biogenesis and Cholestasis in Psc
100407	Jian	Chen	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 01	Cellular Senescence-Triggering Dysfunction of Hepatocyte Aggravates Autoimmune Liver Injury
100679	Fan	Yang	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 01	Immunoregulatory Myeloid Cells Counter T Cell Activation in Aih by Exosome-Mediated Metabolic Shift
100947	Xiaoli	Fan	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 02	Msc-Ev Protects Against Immunological Liver Injury by Suppressing Ferroptosis Via Nrf2/Gpx4 Axis
100954	Xiaoli	Fan	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 02	Targeting Monocytes Via Ccl2/Ccr2 Axis in Autoimmune Hepatitis by Macrophage-Derived Exosomes
101938	Nupur	Sharma	India	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 02	Bile Multi Omics Provide Molecular insight and Classify Signatures of Carcinoma of Gall Bladder
102064	Makiko	Taniai	Japan	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 02	The Analysis of Risk Factors for Hepatocellular Carcinoma in Patients with Autoimmune Liver Disease
100049	Yi	Shen	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 03	Low Serum Complement is Common in Autoimmune Hepatitis and is Related to High Serum Immunoglobulin G
100057	Chen	Huang	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 03	Glucose Metabolism Reprogramming of Neutrophils in Autoimmune Hepatitis
100139	Fan	Yang	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 03	Multi-Omics Reveal Underlying Mechanisms of Drug-Response in Pbc/Aih Variant Syndrome
100239	Takatoshi	Nawa	Japan	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 03	Identification of High-Risk Group for Relapse in Autoimmune Hepatitis Patients
100387	Sung Hwan	Yoo	South Korea	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 03	Azathioprine on Risk of Extrahepatic Malignancy with Autoimmune Hepatitis: A Nationwide Claims Study
100549	Leyu	Zhou	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 03	Association of Sarcopenia with Treatment Response and Outcomes in Non-Cirrhotic Pbc Patients
100766	Katrina Nicole	Mejia	Philippines	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 03	A Rare Case of Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome in A Filipino Adult
100871	Li	Zhang	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Analysis of Diagnostic Predictors in Patients with Pbc-Aih Overlap Syndrome from Aih
101086	Tingting	Lv	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Clinical Characteristic and Prognosis of Premature Ductopenic Variant of Primary Biliary Cholangitis
101092	Kanwal	Butani	Pakistan	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Clinical, Serological and Histological Features of Autoimmune Liver Diseases
101120	Tingting	Lv	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	A Worse Subgroup of Pbc: Jaundice in Patients with Ductopenia
101179	Ahmet Alp	Unat	Turkey	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Developing A Baseline Data-Driven Prognostic index for Primary Biliary Cholangitis
101223	Sylvia	Drazilova	Slovakia	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Late Udca Response is Associated with Worse Prognosis of Pbc Patients Compared to Early Response
101308	Xiao	Han	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Building Hepatic Mri Models Predict Histopathological Severity and insufficient Response in Aih
101349	Muhammed Bahaddin	Durak	Turkey	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Endoscopic Management of Primary Sclerosing Cholangitis: Clinical Outcomes at A Tertiary Center
101430	Shuxiang	Li	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Scoring System is Prognostic Model of Primary Biliary Cholangitis Treated with Udca and Fenofibrate
101516	Yunling	Xue	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Genetic Link Between Periodontitis and Liver Diseases: A Mendelian Randomization Study
101630	Linxiang	Huang	China	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Pyroptosis Plays A Key Role in Primary Biliary Cholangitis in Mice
102016	Dilara	Turan Gökçe	Turkey	Oral	March	28	Thursday	PM	Autoimmune and Cholestatic Disease 04	Urinary Tract Infection and Pyuria in Primary Biliary Cholangitis
100062	Shuai	Chen	China	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 01	Spatiotemporal Immunometabolic Landscape Driven by the Mas Signaling in Acute Liver Injury
100983	Yangjie	Li	China	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 01	Genetic Risks of "One-Pill" Nsaids induced Liver Injury: A Real-World Study
101200	Zikun	Ma	China	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 01	Hepatic Mum1 Expressions Distinguish Drug-induced Liver Injury from Acute-onset Autoimmune Hepatitis
101201	Mio	Tsuruoka	Japan	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 01	Current Status and Safety of Ici Rechallenge for Patients with Imh at Our Hospital
101864	George	Lau	Hong Kong	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 01	Clinical Features of Acute Drug-induced Liver Injury with Pathological Severe Hepatic Inflammation
101930	Yu	Akazawa	Japan	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 01	Close Relationship Between Hepatotoxicity and Adverse Events of Other Organ induced by ICI Therapy
100044	Farhana	Kayani	Pakistan	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 02	Five-Year Single-Center Experience in Acute Hepatotoxicity Due to Herbal Medications from Pakistan
100569	En-Qiang	Chen	China	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 02	N-Acetylcysteine Can Accelerate the Recovery of Drug-induced Cholestatic Liver Injury
100739	Yasuyuki	Komiyama	Japan	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 02	Usefulness of Recum As A Diagnostic Criterion for Drug-induced Liver Injury in Japanese Patients
100906	Yang	Zhi	China	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 02	Efficacy of Magnesium isoglycyrrhizinate in Liver Injury after Receiving Novel Antineoplastic Agents
100910	Yinuo	Dong	China	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 02	Efficacy of Mgig Compared to Steroids in Liver Injury after Novel Antineoplastic Therapy
101082	John Derek	Clutario	Philippines	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 02	Late onset Efavirenz induced Liver toxicity in A 17-Year-Old, Filipino, HIV Patient
101278	Yan	Wang	China	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 02	Ctcae System Upgrades Severity of Icis induced Liver Injury Than Dili Grading Systems
101402	Tiantian	Guo	China	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 03	Clinicopathological Features and Outcomes of Scutellaria (Huang Qin)-induced Liver Injury
101480	Amar	Ranjan	India	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 03	Non-Alcoholic Fatty Liver Disease Following ChemoTherapy
101490	Hiroteru	Kamimura	Japan	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 03	Analysis of international Comparisons of Adverse Drug Reaction Reports in Fda and Pmda Databases
101491	Farhana	Kayani	Pakistan	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 03	Impact of Prior Drug Allergies on Severity of Dili, A Study from Tertiary Care Hospital, Pakistan
101593	Maxine andrea T	Garcia	Philippines	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 03	N-Acetylcysteine Prophylaxis for Anti-Tuberculosis Drug induced Hepatotoxicity: A Meta-Analysis
101684	Noriyo	Yamashiki	Japan	Oral	March	28	Thursday	PM	Drug-induced Liver Injury 03	Usefulness of A New Diagnostic Criteria in Patients Suspected of Drug-induced Liver Injury
100041	Xiaoquan	Liu	China	Oral	March	28	Thursday	PM	Hepatitis B - Basic 01	Dopamine Analog inhibits the HBV Surface and E Antigen Expression by Upregulation Jak/Stat Pathway
100497	Kana	Shiraishi	Japan	Oral	March	28	Thursday	PM	Hepatitis B - Basic 01	The Factor Affecting Hbsag Reduction after Nasal therapeutic Vaccine in Chronic Hepatitis B Patients
100628	Shengxia	Yin	China	Oral	March	28	Thursday	PM	Hepatitis B - Basic 01	Highly Expressed Ctl4a on B Cells Defected Bcr Signal to inhibit the Secretion of Anti-Hbs in Chb
100691	Xin	tong	China	Oral	March	28	Thursday	PM	Hepatitis B - Basic 01	Comprehensive Analysis of Chb Concurrent with Nafld : A Proteomics Report Based on Liver Samples
100855	Tao	Shen	China	Oral	March	28	Thursday	PM	Hepatitis B - Basic 01	Mirna106B-3P Down Regulates Pcgf3 and inhibits Cell Metastasis in HBV-Related Hepatoma Carcinoma
101155	Hang	Le	Vietnam	Oral	March	28	Thursday	PM	Hepatitis B - Basic 02	The Differentiation of Treg and Th17 Cells in Patients with Chronic Hepatitis B in Different Stages
101224	Bingqian	Qu	Germany	Oral	March	28	Thursday	PM	Hepatitis B - Basic 02	Adenosine Sulfamate Analogs inhibit HBV Rna Synthesis and Accelerate the Decay of Viral Transcripts
101227	Guiwen	Guan	China	Oral	March	28	Thursday	PM	Hepatitis B - Basic 02	Multi-Omics Panoramic Analysis of HBV integration in the HBV-Integrated Cell Line Pbc/Prf/5
101244	Deyao	Li	China	Oral	March	28	Thursday	PM	Hepatitis B - Basic 02	Ig2Bp1 Promotes HBV Replication Via Regulating HBV Rna Stability in An M6A-Dependent Manner
101573	Jun	inoue	Japan	Oral	March	28	Thursday	PM	Hepatitis B - Basic 02	Deep Sequencing Analysis of HBV Evolution in Elderly Cases of InterspoUSAI Transmission
101939	Hartiowidi	Yuliiawuri	Indonesia	Oral	March	28	Thursday	PM	Hepatitis B - Basic 02	Primer Design of isothermal Amplification for Detection of Hepatitis B Virus Core Gene in Indonesia
100363	Nicole Allyson	Chua	Philippines	Oral	March	28	Thursday	PM	Hepatitis B - Basic 03	Knowledge, attitudes and Practices (Kap) of Adult Filipinos towards Viral Hepatitis
100425	Lili	Wu	China	Oral	March	28	Thursday	PM	Hepatitis B - Basic 03	Iln-Γ+ Th1 Promotes Hbsag Loss by Activating Intrahepatic Trm through inducing M1 Polarization
100482	Taiyu	He	China	Oral	March	28	Thursday	PM	Hepatitis B - Basic 03	Anti-Pd-1 Antibody Combined with Etv and Peg-Iln-Α Enhances Anti-HBV Efficacy in Aav-HBV Mice
100907	Yi-Qi	Liu	China	Oral	March	28	Thursday	PM	Hepatitis B - Basic 03	Serum N-Glycan for Diagnosing Liver Fibrosis in Chronic Hepatitis B Patients with Normal Alt Levels
101036	Hongbo	Shi	China	Oral	March	28	Thursday	PM	Hepatitis B - Basic 03	Alcohol induced Dendritic Cell and It'S Exosome Promotes Specific T Cell Immunity in HBV Infection
100077	Takanori	Suzuki	Japan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 01	Kinetics of Itact-Hbcrag and -Hbsag Assays in Chronic Hepatitis B Patients with Hbsag Seroclearance
100137	Thanapat	atthakitmongkol	Thailand	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 01	Effects of Vitamin D and Calcium on Bones in Chronic Hepatitis B Patients Treated with Tdf
100157	Kuan-I	Lee	Taiwan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 01	Unawareness of Hepatitis B Infection and Severity of Hepatocellular Carcinoma
100176	Seng Gee	Lim	Singapore	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 01	Stopping Oral Therapy in Chronic Hepatitis B Using Hbsag Thresholds: Metaanalysis & Meta-Regression
100203	Mohamed	Mahboob Ali	Malaysia	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 01	The Correlation Between Interleukin-6 and the Progression of Chronic Hepatitis B
100214	Jiwei	Fu	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 02	Establishment of A Predictive Model of Myelosuppression in Patients with Chb Treated with Peg-Iln
100226	Terry Cheuk-Fung	Yip	Hong Kong	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 02	Tenofovir Disoproxil Fumarate Raises Long-Term Fracture Risk in Elderly Chronic Hepatitis B Patients
100228	Wenjuan	Zhao	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 02	Lipid Safety of Tenofovir Alafenamide During 96-Week Treatment in Chronic Hepatitis B Patients
100270	Mingqin	Lu	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 02	High Normal Alt is An indicator for Better Response to Antiviral Therapy in Chronic Hepatitis B
100274	Grace	Wong	Hong Kong	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 02	High Burden of Compensated Advanced Chronic Liver Disease (CaclD) in Diabetic Chronic Hepatitis B
100308	En-Qiang	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 03	Chb Patients Receiving Nas Therapy and Achieving Hbsag Loss Can Safely Discontinue Medication
100309	En-Qiang	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 03	Safety of Biological Agents Used in Autoimmune Diseases Patients with inactive Hbsag Carrier State
100333	Jonggi	Choi	South Korea	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 03	Longitudinal Changes in Renal Function in Patients with Chronic Hepatitis B on Antiviral Treatment
100382	Xingmei	Liao	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 03	Effects of Etv and Tdf on the Incidence and Severity of Covid-19 in Chronic Hepatitis B Patients
100392	Hoang	Hai	Japan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 03	Soluble Pd-1 and BtlA Proteins As Biomarkers for Predicting the Anti-HBV Treatment Responsiveness
100454	Liyuan	Zhang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 04	Taf and Tdf for Chinese Assisted Reproductive Pregnant Women with HBV infected: A Prospective Study
100548	Guanhua	Zha	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 04	Humoral Responses after Covid-19 Vaccination and Breakthrough Infection in Chb Patients
100566	Yao-Chun	Hsu	Taiwan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 04	Comparing M2Bpgi, Apri and Fib4 for Liver Fibrosis Diagnosis with Pathology in Chronic Hepatitis B
100587	Xintong	Huang	Australia	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 04	Sex, Age and Geographic Disparities in Hepatitis B Randomised Trials: A Meta-Epidemiological Study
100669	Ding-Lian	Wang	Taiwan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 04	Deep Sequencing of the HBV Genome in Taiwan: Risk of HCC from Primary and Secondary Genotypes
100765	Qing-Lei	Zeng	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 05	Expected Eight-Week Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B Virus
100768	Soichi	Arasawa	Japan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 05	Evolution of HBV Genomic Structures without Selective Pressure of Antiviral Treatment
100870	Vicki Wing-Ki	Hui	Hong Kong	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 05	Assessing Liver Cirrhosis Progression Under the Baveno Vii Definition Using Hidden Markov Model
100877	Qijuan	Zang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 05	Dynamic Liver Volume Changes Predict Re-Compensation of HBV-Related Decompensated Cirrhosis
101046	Min-Ran	Li	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 05	Investigation on Current Situation and Trend of Antiviral Treatment for Chronic Hepatitis B in China
101055	Yasuhito	Tanaka	Japan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 06	Exploratory Biomarkers Hbcrag and HBV Rna: Relationship with Bepiroviren Response in B-Clear
101125	Bei	Jiang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 06	Association of Serum Virology indicators with Immune-Mediated Hepatic Injury in Chronic HBV
101188	Shan	Fu	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 06	Risk of Mtct after Amniocentesis in Pregnant Women with HBV: A Systematic Review and Meta-Analysis
101239	Jin	Li	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 06	Functional Delivery of Mirnas Via Hbsag: Modulation of Monocyte and Inflammation Progression in Chb
101385	Tung-Hung	Su	Taiwan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 06	The Gaad Score Predicts HCC in HBV-Related Cirrhosis Patients after 6-Year Antiviral Therapy
101390	Rong	Fan	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 07	High Accuracy Prediction Model for Hbsag Loss During Long-Term Antiviral Therapy in Chb Patients
101391	Qin	Ning	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 07	Efficacy of Combination Treatment of Tlr7 Agonist and Anti-Pd-L1 in Virally Suppressed Chb Patients
101413	Haiying	Zhang	China	Or						

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
101450	Fehmi	Tabak	Turkey	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 07	Risk Factors for Low Level Viremia in Chronic Hepatitis B Patients Receiving Antiviral Treatment
101537	Leah Anne E.	Legaspi	Philippines	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 07	Coffee Consumption on Advanced Fibrosis and Cirrhosis Among Hepatitis B Patients: Meta-Analysis
101546	Hung-Yao	Lin	Taiwan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 08	Lower Hbcrag Level Associates with Higher Spontaneous Hbeag Seroclearance Rate in Chb Patient
101591	Yuxuan	Song	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 08	Efficacy and Safety of Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients in Real World
101657	Yu-Chen	Fan	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 08	A Model to Identify the Starting of Antiviral Therapy in Gray Zone Patients with Chronic Hepatitis B
101716	Md Jahangir	Alam	Bangladesh	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 08	Biochemical and Serological Characterization of Chronic Hepatitis B Infection in Sylhet
101767	Chuan-Bo	Huang	Taiwan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 08	Effectiveness of HBV Vaccination in Hemodialysis Patients Negative for Anti-Hbs
101807	Man-Fung	Yuen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 09	Alg-000184 ± Entecavir Results in Substantial HBV Antigen Declines in Untreated Hbeag+ Hepatitis B
101812	Jing	Chen	Hong Kong	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 09	Major Obstacles to "Functional Cure" with Novel Anti-Viral Therapy for Chb - A Systemic Review
101813	Jinlin	Hou	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 09	Alg-000184 (100 Mg) + Etv Leads to Stronger Antiviral Effects Compared to Etv Alone in Hbeag+ Chb
101816	Edward	Gane	New Zealand	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 09	Alg-000184 Has Favorable Antiviral Effect & Safety in Untreated Asian/Non-Asian Hbeag- Chb Subjects
101836	Muh	Rasyak	Indonesia	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 09	Mutational Effects on Hbsag in Occult Hepatitis B Among Pregnant Women: in-Silico Study, Indonesia
101871	George	Lau	Hong Kong	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 10	HBV Recurrence after Liver Transplantation Associated with Non-Compliance to "Up to Seven" Criteria
101881	George	Lau	Hong Kong	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 10	Different Guidelines on Classification of Grey Zone in Those with Normal ALT and Detectable HBV Dna
101885	Katerina	Glavini	Switzerland	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 10	Efficacy and Safety of Xanesiran with and without An Immunomodulator in Chronic Hepatitis B
101933	Shaoqiu	Zhang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 10	Clinical Outcomes of Hbeag-Negative Chb Patients in Indeterminate Phase with Normal Alt
101944	Jian	Wang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 10	Clinical Outcomes of Hbeag-Negative Chb Patients with Hbsag Less Than 100 Iu/MI
101958	Yuan Yuan	Li	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 11	Hbeag-Positive Chb Patients in Indeterminate Phase Associated with High Risk of Significant Fibrosis
101964	Jeong	Heo	Republic of Korea	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 11	Multi-Method Analysis Identifies Genotypes in All Evaluated Participants on-Na, B-together Study
101967	Ravinder	Singh	India	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 11	Scrnaseq Reveals High Expression of Cxcl8 Resident Immune Cells with Fibrosis in Low Hbsag Patients
102017	Abul Hayat	Manik	Bangladesh	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 11	Virological and Histological Characteristics of Chronic Hepatitis B Virus Patients with Normal Alt
102039	Purnima	Tyagi	India	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 11	Investigation of HBV Cccdna-Bound Proteins in Liver Biopsies from HBV for therapeutic Targeting
200111	Zhilliang	Gao	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 12	Functional Hbsab Responses Induced by Brl-179 Are Strongly Associated with Improved Hbsag Loss
200115	Chan	Xie	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 12	Everest Project'S 5-Year Update: Efficacy of Pegifn-A Therapy in Hbeag- Chb Patients in China
200148	Yanjie	Lin	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 12	The Correlation Between Hla-Dr+ Cd38+ Cd8+ T Cell Changes and Efficacy During Ifn-Based Chb Treatment
200285	Sue L	Currie	United States	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 12	First-in-Human, First-in-Class, Phase 1B Preliminary Safety Data of Vron-0200, A Novel Checkpoint Modifier Containing Immunotherapy, for HBV Functional Cure
100319	Sudhamshu	Kc	Nepal	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 13	Efficacy of Hepatitis B Vaccine in Liver Cirrhosis Patients
100356	Tingting	Peng	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 13	Maternal Infection with Hepatitis B and Maternal and Neonatal Outcomes
100358	Jing	Liang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 13	Etv, Tdf and Taf on Recurrence after Curative Rfa in Hbeag-Negative HBV-Related HCC Patients
100375	En-Qiang	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 13	Switching to Tmf is Effective for Etv or Taf Monotherapy in Patients with Hypoviremia
100421	Hsiang-Hsuan	Chuang	Taiwan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 13	HBV Pres1 Variant Mediates the Protective Effect of Ntcp S267F Variant Against HCC in Chb Patients
100430	Na	Gao	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 13	Histological Characteristics in Functional Cure Post Peg-Ifn-Based Therapy
100447	En-Qiang	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 13	Antiviral Therapy Can Improve the Health-Related Quality of Life in Chb Patients with Normal Alt
100453	En-Qiang	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 14	Anti-Fibrosis Effect of Traditional Chinese Medicine Compound Biejiaeruan in Chb Patients
100485	Guixin	Li	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 14	Pan-Genotypic Association of G1896A Mutant with HBV Dna or Advanced Liver Diseases: A Meta-Analysis
100544	Fajuan	Rui	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 14	Development of A Diagnostic Model for Hepatic Inflammation in Patients of Chb with Hs Based on MI
100545	Fajuan	Rui	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 14	Determining of Transient Elastography Cutoff for Advanced Fibrosis in Patients of Chb with Hs
100560	Ruixin	Song	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 14	Immunogenicity of Sars-Cov-2 Vaccination Among Patients with Chronic Liver Disease
100562	Qianqian	Li	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 14	Immunogenicity of A Booster Sars-Cov-2 Vaccination in Patients with Chronic Liver Disease
100570	Wenjing	Ni	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 14	A Novel Model for Advanced Fibrosis and Cirrhosis Diagnosis for Chb Patients with Hepatic Steatosis
100582	Xiaoming	Xu	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 15	Novel Algorithms for Predicting Advanced Fibrosis in Chb Patients with Concurrent Hepatic Steatosis
100595	Wenjing	Ni	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 15	The Diminished Accuracy of Non-invasive Tests for Significant Fibrosis in Chb Patients with MASLD
100599	Fei	Tang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 15	Explore the Decrease of Hbsag in Patients with Compensatory Cirrhosis During Peg-interferon Therapy
100606	Qianqian	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 15	Comparison of Markers for Diagnosing Significant or Advanced Fibrosis in Patients with Chb
100607	Jiayin	Wang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 15	Hbsag Decline in Peg-Ifn Treated Hepatitis B with Fatty Liver is Similar to Non-Fatty Liver Patients
100608	Jiayin	Wang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 15	Analysis of PIt Changes in Patients with Cirrhotic Hepatitis B Patients Treated with Peg-interferon
100641	Qiao	Tang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 15	Pgrna and Hbcrag Closely Correlated with Cytokines in Hbeag-Positive Pregnant Patients in Pregnancy
100642	Shaowen	Jiang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 16	Ifn-Α Provides Dual Benefits of Reducing HCC and Facilitating Hbsag Loss for Na-Treated Chb Patients
100701	Chan	Xie	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 16	The Everest Project'S 5-Year Update: Efficacy of PegifnΑ Therapy in Na-Suppressed Hbeag Negative Chb
100730	Tianjing	Zhang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 16	Clinical Study on the Efficacy and Safety of Interferon in Compensatory Hepatitis B Cirrhosis
100754	Xiaonan	Wu	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 16	Chb Patients with Extremely Low-Level Viremia - Clinical Characteristics and Prognosis.
100771	En-Qiang	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 16	The Incidence of Renal Tubular Absorption Dysfunction Among Patients with Nuc Plus PegifnΑ2B Therapy
100772	Lei	Ma	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 16	Efficacy of Antiviral Therapy in Alt Normal Chronic HBV Infection
100781	En-Qiang	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 16	Sexual Dysfunction in Female Chb Patients with Nucleoside(T) Analogues Therapy
100862	Qijuan	Zang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 17	Liver Volume Re-Compensation in HBV-Related Decompensated Cirrhosis after Nuc Therapy
100886	Yunling	Xue	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 17	Higher Risk of Disease Progression in the Grey Zone Relative to inactive Chronic Hepatitis B
100889	Mingyang	Feng	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 17	Antiviral Effect in Patients with Chronic Hepatitis B Infection in the Indeterminate Phase
100921	Yan	Huang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 17	NaflD Comorbidity Predicts Higher Alt and Liver Stiffness: A Longitudinal Study in Chb Patients
100930	Vicki Wing-Ki	Hui	Hong Kong	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 17	Elevated Risk of In Clinical Outcomes Untreated Hbeag-Positive Chb Patients in Indeterminate Phase
100931	Vicki Wing-Ki	Hui	Hong Kong	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 17	Prolonged Indeterminate Phase in Untreated Chronic Hepatitis B-infected Patients
100960	onuma	Sattayalertyanyong	Thailand	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 17	Long-Term Effects of Tenofovir and Entecavir Cessation in Hbeag Negative Chronic Hepatitis B
100974	Zhang	Mengdi	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 17	The Impact of Long-Term Entecavir Treatment on Renal Safety in Patients with Chronic Hepatitis B
100977	Baiguo	Xu	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 18	Study on Replication-Competent HBV Dna in Hepatitis B Cirrhosis with HCC Patients
100982	Irdina S	Nadziruddin	United Kingdom	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 18	Multi-Parametric Mri Identified Chronic Hepatitis B Patients with Subclinical Liver Inflammation
100986	En-Qiang	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 18	The Effect of Tenofovir Amibufenamide on Lipid Metabolism
101045	Youwen	Tan	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 18	Diagnostic Accuracy of Fast Score, Nfs, Fibroscan, and Fib-4 in Chb Patients with NaflD
101094	David	Wong	Canada	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 18	Engagement in Care, not Antiviral Therapy for All, is Important to Reduce Early Mortality from HBV
101115	Hasmik	Ghazinyan	Armenia	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 18	Characterization of Genotypes,Subtypes and Prevalence of Occult HBV in Chronic Liverdisease and HCC
101121	Haoyao	Wang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 18	Non-invasive Mre Assessment of Liver Injury in Hbeag-Negative Patient with Chb: A Case Report
101130	Dawu	Zeng	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 19	Optimal Alt Cut-off Values in the Grey Zone of HBV Infection
101136	Lu	Fengmin	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 19	The Negative Relationship Between HBV Dna and Liver Damage Loss Before Hbeag Clearance in Chb
101174	Jun	inoue	Japan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 19	A Validation Study of Fal-1 Score for Predicting HCC Risk in Chb Patients Treated with Nas
101222	Riaz	Channa	Pakistan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 19	Reactivation of HBV in Patients with Resolved HBV Infection after Receiving Daa Treatment for HCV
101265	Qin	Ning	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 19	Tenofovir Alafenamide for Treatment-Na&luml;Ve and Nucleos(T)Ide with Hepatitis B Virus Infection
101357	Yameng	Sun	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 19	On-Treatment Liver Stiffness Measurements Predict Liver-Related Events in Patients on HBV Therapy
101382	Tung-Hung	Su	Taiwan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 19	M2Bpgi Stratifies HCC Risks in Chronic HBV-Related Cirrhosis Patients after 6-Year Antiviral Therapy
101428	Hanisha	Hemnani	Pakistan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 20	To Determine the Risk Factors of Hepatitis B in Children at Jinnah Postraduate Medical Center
101437	Qing	Ye	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 20	The Effect of Peg-IfnΑ2B on Metabolic Status in Patients with Chb Combined with NaflD
101454	Srijaya	Sreesh	India	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 20	All That Glitters is not Gold : Thinking Beyond Cams
101484	Murat	KeKilli	Turkey	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 20	Neutrophil to Lymphocyte Ratio and Mean Platelet Volume in Predicting HBV Dna Negativity
101488	tongjing	Xing	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 20	Development and Validation of New Predictive Model for Immune tolerance of Chronic HBV Infection
101489	Xiyao	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 20	Spd-1 and Spd-L1 Levels Predict Functional Cure in Chb Patients after Nas and Peg-IfnΑ Therapy
101520	Alice	Lee	Australia	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 20	Achieving Hepatitis B Elimination in the Pacific Islands: Test/Treat is the Way forward in Kiribati
100975	Qijuan	Zang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 21	Liver Volume Re-Compensation in HBV-Related Decompensated Cirrhosis after Nuc Therapy
101627	Qiao	Tang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 21	Little Liver Disease Progression after Long-Term Drug withdrawal in Hbeag Positive Postpartum Woman.
101705	Tai-Chung	Tseng	Taiwan	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 21	Optimal Threshold of M2Bpgi for Predicting Minimal HCC Risk in Chb Patients with Antiviral Therapy
101743	Lilian Y	Liang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 21	Effects of Tenofovir Alafenamide on the Risk of Hepatocellular Carcinoma in Hong Kong
101756	Zhiyi	Zhang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 21	A Random Survival forest Model for Predicting Hbeag Seroclearance in Chb Patients Treated with Nas
200019	Hao	Wang	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 21	Impact of Different Alt Thresholds on the Treatment Eligibility of Patients with Chb
200097	Fengmin	Lu	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 21	Enhancer 1 Unevenly Activates the Pres1 Promoter of Integrated HBV Dna and Impacts Hbsag Secretion
200252	Yuanmei	Chen	China	Oral	March	28	Thursday	AM	Hepatitis B - Clinical 21	Clinical Predictors of Functional Cure in Chb Patients Treated with Pegylated interferon Alpha-2B
101165	Asra	Asgharzadeh	United Kingdom	Oral	March	28	Thursday	PM	Hepatitis C - Basic 01	Cost of Hepatitis C Virus Self-Testing in Malaysia: A Micro-Costing Study
101894	Zayar	Phyo	Japan	Oral	March	28	Thursday	PM	Hepatitis C - Basic 01	Hepatitis C Virus (Hcv) Transmission Among Japan'S Limited Risk Groups
200246	Prihantini	Prihantini	Indonesia	Oral	March	28	Thursday	PM	Hepatitis C - Basic 01	Improving Hcv Diagnosis: Precision Classification with Data Mining for Identifying Suspected Patients
100316	Jonggi	Choi	South Korea	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 01	Improvement of Hepatitis C Virus Care Cascade by in-Hospital Reflex Testing Alarm-C (Real-C) Model
100467	Yuki	Tahata	Japan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 01	Factors of Aggravation of Esophagogastric Varix after Daa in Hcv Decompensated Cirrhotic Patients
100531	Shifu	Li	China	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 01	A Government-Leading Multi-Organization Collaborative Model for Hcv Elimination in Yuxi, Yunnan
100612	Binu	John	United States	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 01	Liver Stiffness Measurement and Risk of Hepatocellular Carcinoma after Hcv Eradication in Cirrhosis
101032	Brian	Conway	Canada	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 01	Long Term Outcome Following Hcv Treatment with Glecaprevir/Pibrentasvir in People Who Use Drugs
101158	Mina	Nakagawa	Japan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 02	Association of Metabolic Abnormalities with HCC Development and Survival in Chc Patients after Svr
101286	Fehmi	Tabak	Turkey	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 02	Real World Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Naive Chronic Hepatitis C Patients
101668	Hiroshi	Naito	Japan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 02	Elevated Ggt with Metabolic Factors Enhances HCC Development after Hcv Eradication
101877	Fanpu	Ji	China	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 02	Real-World Effectiveness and tolerability of interferon-Free Daa for Hcv Patients with Genotypes 1-6
101882	Fanpu	Ji	China	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 02	Mortality Rates Among Patients Successfully Treated for Hcv: A Real World Multinational Cohort Study
102060	Shuntaro	Obi	Japan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 02	attention not only to Hepatocellular Carcinoma But Also to Carcinogenesis of All Organs
100106	Peng	Huang	China	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 03	Impact of Daas on HCC Risk in Chinese Hepatitis C Patients: A 10-Year Follow-Up Study
100142	Chen-Hua	Liu	Taiwan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 03	Dynamic Serum M2Bpgi to Predict Hepatic Fibrosis in HCV Patients Achieving Svr to Daas
100194	Qing	Ye	China	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 03	Non Specialist Training : An Effective Method for Micro-Elimination of Hepatitis C in Hospital
100250	Satoru	Joshita	Japan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 03	Clinical Utility of HCV Core Antigen Measurement for HCVab-Positive Patients towards HCV Elimination
100326	Yu-Ping	Chang	Taiwan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 03	Long-Term Serum Ferritin Dynamics in Patients Receiving Antiviral Treatment for HCV Infection
100504	Yongzi	Wei	China	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 03	Collaboration with Community and Hospital Contributes to HCV Elimination in Database
100528	Fang	Cao	China	Oral	March	28	Thursday</			

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
100542	Yongrui	Yang	China	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 04	Real-World Study of Sofosbuvir/Velpatasvir for Cirrhotic Patients with Genotype 3 HCV Infection
100592	Ashley	Tiong	Singapore	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 04	Baseline Fib4 is Superior to Fib4 at Svr12 to Predict HCC Occurrence Following Daa-attained Svr12
100784	Alyssa	Sim	Singapore	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 04	Evaluating HCV Point-of-Care Testing - A Real-World Study on People Who Inject Drugs in Singapore
101031	Brian	Conway	Canada	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 04	Comparing Sofosbuvir/Velpatasvir & Glecaprevir/Pibrentasvir for HCV Treatment in Drug Users
101064	Qing	Lin	China	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 04	Sexual Transmission was Common in Recently Acquired HCV infected Patients with HIV
101072	Anoshia	Fahad	Pakistan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 04	Frequency of Cognitive Impairment in Patients with Chronic HCV and Its Correlation with Ctp Score
101287	Hiroko	Ikenaga	Japan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 05	The Risk for Tumor Progression of HCV-Related Hepatocellular Carcinoma after Curative Treatment
101298	Riaz	Channa	Pakistan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 05	Treatment Outcome of Patients Undergoing Hemodialysis with Chc on the Sof and Velpa Regimen
101345	Marianne	Alanko Blome	Sweden	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 05	37 Years with MalmÖ Needle Exchange Program at the Center: from HIV Prevention to HCV Elimination
101394	Qiran	Zhang	China	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 05	HCV Screening in General Populations and High-Risk Population in Areas with Low Prevalence in China
101459	Hafiz	ather	Pakistan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 05	Efficacy of Velpatasvir and Sofosbuvir Combination Therapy in Chronic HCV Patients
101478	Putra	Nur Hidayat	Indonesia	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 05	Changes in the Degree of Liver Steatosis and Lipid Profile of Hepatitis C Patients at Svr12
101505	Vahe	Azatyán	Armenia	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 06	The State of the oral Mucosa in Patients with Viral Hepatitis C in Armenia for the Period 2021-2022
101884	atsuhiko	Morita	Japan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 06	Characteristics of Hepatitis C Patients Undergoing oral Antiviral Therapy at Our institution
102018	Rene John	Febro	Philippines	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 06	Concurrent Management of Chronic Hepatitis C and Advanced Hepatocellular Carcinoma: A Case Report
200090	Xuemei	Tao	China	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 06	Nomogram for Predicting Hepatocellular Carcinoma in HCV-Associated Cirrhosis Patients
200091	Shuntaro	Obi	Japan	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 06	"Stiffness" Resolution is Uncompleted with the HCC Incidence Reduction in Advanced Fibrosis
200192	Graham	Cooke	United Kingdom	Oral	March	28	Thursday	PM	Hepatitis C - Clinical 06	Vietnams: A Strategic Post-Licensing Randomised Trial of Direct Acting Hepatitis C Antivirals
100276	Feng	Ren	China	Oral	March	28	Thursday	PM	Hepatitis Delta 01	Crispr/Cas13A-Assisted Accurate and Portable Hepatitis D Virus Rna Detection
100465	Robert	Wong	United States	Oral	March	28	Thursday	PM	Hepatitis Delta 01	Hepatitis Delta Virus Testing and Prevalence Among Veterans with Chronic Hepatitis B in the USA
100802	Pietro	Lampertico	Italy	Oral	March	28	Thursday	PM	Hepatitis Delta 01	Bulevirtide Improves Virologic & Biochemical Response in Non Or Partial Responders with Chd
100812	Tarik	Asselah	France	Oral	March	28	Thursday	PM	Hepatitis Delta 01	Efficacy & Safety of Bulevirtide in Combination with Pegylated interferon Α-2A in Patients with Chd
100990	andrew	Vaillant	Canada	Oral	March	28	Thursday	PM	Hepatitis Delta 01	Compassionate Use of Rep 2139-Mg in HBV/HDV Infection with Advanced Liver Disease
100610	Minaam	Abbas	United Kingdom	Oral	March	28	Thursday	PM	Hepatitis Delta 02	High Prevalence of Hepatitis D by Double Reflex Testing of Hbsag Positive individuals in Pakistan
100970	Pavel	Bogomolov	Russia	Oral	March	28	Thursday	PM	Hepatitis Delta 02	Bulevirtide in Patients with Chronic Hepatitis D - Real World Experience
101229	Tsung-Hui	Hu	Taiwan	Oral	March	28	Thursday	PM	Hepatitis Delta 02	Development of A Network for Hepatitis D Registration and Study in Taiwan: Tadr - An Update in 2023
101302	Riaz	Hussain	Pakistan	Oral	March	28	Thursday	PM	Hepatitis Delta 02	Efficacy of Pegylated interferon-Alpha-2A in HDV: Experience from the Tertiary Care Hospital
101770	Loreta A	Kondili	Italy	Oral	March	28	Thursday	PM	Hepatitis Delta 02	Clinical Profile of Patients with Chronic HDV Infection by the Nationwide Italian Piter-Cohort
101793	Cihan	Yurdaydn	Turkey	Oral	March	28	Thursday	PM	Hepatitis Delta 02	HCC Risk is Similar in HDV Patients with Viral Response to Treatment Compared to HBV Patients
102023	Cihan	Yurdaydn	Turkey	Oral	March	28	Thursday	PM	Hepatitis Delta 02	Lonafarnib-Based Regimens Associated with Long-Term Apparent Cures in Chronic Hepatitis Delta
102053	Cihan	Yurdaydn	Turkey	Oral	March	28	Thursday	PM	Hepatitis Delta 02	The Course of Covid-19 Infection in Patients with Chronic Hepatitis Delta
200187	Sainzaya	Batmunkh	Mongolia	Oral	March	28	Thursday	PM	Hepatitis Delta 02	Pegylated interferon Α for Patients with Chronic Hepatitis D in Mongolia
100655	Hung-Yu	Sun	Taiwan	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 01	Apolipoprotein J Facilitates Diabetic Nephropathy Progression Via Mtor-Tfeb-Autophagy Axis
100890	Alankrita	Madhur	India	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 01	All Pediatric Fatty Liver Diseases Are not Non-Alcoholic Fatty Liver Disease (Nafld)
101056	Wei	Zhang	China	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 01	Clinical Characteristics, Genotype and Outcome of Type 2A Hereditary Hemochromatosis in China
101318	Moinak	Sen Sarma	India	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 01	Can We Predict Outcome in Galactosemia?: Experience from A Tertiary Centre of 51 Patients
101486	Pengyao	Yang	China	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 02	Serum Iron Overload Activates Smad Pathway and Hecidin Expression of Hepatocytes Via Smurf1
101653	Yuki	Hamada	Japan	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 02	Hepcidin-inducer Laennec® Can Sorely Improve Congenital Iron and Copper Metabolism Disorder
101990	Pramod	Gautam	India	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 02	Evaluation of Genetic Markers Contributing to Disease Predisposition in Patients with Mafld/Nafld
101993	Pramod	Gautam	India	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 02	Diagnostic Genetic Markers Implicated in Prothrombotic Phenotypes in Liver Disease Patients
100104	Xiaoxin	Wu	China	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 03	The Remission Strategy for Epp Accompanied with Severe Abdominal Pain and Liver Injury
101211	Jan Bendric	Borbe	Philippines	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 03	Hepatomegaly from Poorly Controlled Type 1 Diabetes: A Rare Case of Mauriac Syndrome
101508	Mohamed	Mahboob Ali	Malaysia	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 03	The Role of Vitamin E in the Treatment of Nonalcoholic Steatohepatitis(NASH)
101783	Amit	Soni	India	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 03	Hepatic Amyloidosis: Unraveling the Mystery !!!
200039	Abu Saleh Md Sadequ	islam	Bangladesh	Oral	March	28	Thursday	PM	Metabolic and Genetic Disease 03	Wilson Disease: Our Observations Over the Past Five Years
100088	Zhe	Dai	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 01	Lipid-Associated Macrophages Fuel Nafld Fibrosis Via Cd36-Mediated Lipid Uptake & Opn Release
100307	Chun-Yan	Niu	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 01	Glp-1Ras Regulate Lipid Metabolism and induce Autophagy Through Ampk/Sirt1 Pathway to Improve Nafld
100313	Chun-Yan	Niu	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 01	Amritriptyline Inhibits Nlrp3 Inflammation Activation Via Suppressing the Asm/Ce Pathway in Nafld
100512	Van Dien	Nguyen	United Kingdom	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 01	Elucidating the Role of Complement C3 in Metabolic-Associated Fatty Liver Disease
100557	Abraham	Shaked	United States	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 01	Donor and Recipient Genetic Interactions: Improving Post-Transplant Diabetes Outcomes
100849	Hirokazu	Takahashi	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 02	A Social Media Listening Study of Patients' Experiences toward Nafld (Listen-Nafld)
100963	Kutbuddin	Abkary	Singapore	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 02	New Ai-Digital Pathology Indices Predict Adverse Clinical Outcomes in Patients with MASLD
100976	Kathleen E.	Corey	United States	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 02	Liver Fibrosis is Associated with Burden of Cardiovascular Disease in Non-Alcoholic Steatohepatitis
101057	Kouchi	Miura	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 02	Ferroptosis is A Cell Death at An Early Stage of MASLD in A Mouse Model
101263	Qin	Ning	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 02	Npc1 Deficiency Mediates Autophagy Impairment in Nafld and Serves As A Target for Nafld Treatment
101275	Akihiro	Seki	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 03	Mesenchymal Stem Cells Restore NASH by Ameliorating Er Stress in the Local Environment of the Liver.
101720	Gary	Huang	Australia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 03	Development of A Novel Cell Line Using Gene Editing to Study Steatotic Liver Disease
101850	Xiaoning	Chen	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 03	Edaravone Promotes the Amp-Activated Protein Kinase to Relieve Nonalcoholic Steatohepatitis in Mice
102054	Kazuyoshi	Kon	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 03	Inkt Cells Are Key Players in the Progression of Murine Steatohepatitis Caused by Western Diet
200128	Yufeng	Pei	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 03	Metabolic-Associated Fatty Liver Disease - Basic 03
200265	Jie	Ma	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 03	Spatio-Temporal Immune Landscape of Tertiary Lymphoid Structures in Non-Alcoholic Steatohepatitis
100063	Han Kiat	Ho	Singapore	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 04	Mechanistic Study of Tyrosine Kinase Inhibitors Against Metabolic-Associated Fatty Liver Disease
100078	Bayasi	Guleng	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 04	Cd18 Deficiency Ameliorates NASH by Inhibiting Lipid Synthesis and Downregulating Th1 Cells in Mice
100182	Ying-Hsien	Huang	Taiwan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 04	Microna 29A Ameliorates NASH by Attenuating the Mavs Pathway and Mitigating Liver Steatofibrosis
100249	Vaibhav	Sapra	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 04	Gsk-3 Β Inhibition for Stimulation of Liver Regeneration in Partially Hepatectomized Rats
100283	Zhiyu	Yang	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 04	Transcriptome Analysis Revealed Fabb5 As A Serum Marker of Metabolic Associated Fatty Liver Disease
100288	onkar	Bedi	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 04	Pharmacological Exploration of Fas Inhibitors for Managing Diabetic & Non Diabetic-Liver Injury
100402	Pavitra	Kumar	Germany	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Basic 04	Oxidative-Cellular Bioenergetics Governs the Telomerase Inhibition-Induced Senescence in Hepatocytes
100503	Hanzhi	Xu	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 05	Pak1 Protects Against Nonalcoholic Fatty Liver Disease Via Suppression of PparΓ
100543	Rafik	Prabowo	Indonesia	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 05	Antioxidative Activity of orange Water Kefir to Improve Liver Tissue in the Hyperlipidemic Rat Model
100552	Sunita	Giri	India	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 05	Entacapone Abrogate Steatotic Liver Disease Progression by Modulating Fto Gene Expression
100744	Xiao	Zhong	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 05	Mett14 Promotes Liver Glucose Production and Liver Steatosis in Obesity by Rna M6A Modification
100780	Mohammad	Azam	Bangladesh	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 05	Role of Serum Ferritin Level in the Diagnosis of Non-Alcoholic Fatty Liver Disease
100818	Aaron Lemuel	ong	Philippines	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 05	A Google Trendstm Analysis on Non-Alcoholic Fatty Liver Disease: A Retrospective infodemiology Study
100820	Aaron Lemuel	ong	Philippines	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 05	A Comparison of the Knowledge and Practices on Non-Alcoholic Fatty Liver Disease Among Physicians
100830	Joel Yeh Siang	Chen	Singapore	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 06	Lessons on Drug Development: A Literature Review of Challenges Faced in MASLD Clinical Trials
100866	Noel	Salvoza	Philippines	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 06	Omentin-1: Implications on Its Role in Diabetes and Metabolic-Associated Fatty Liver Disease
100993	Jishnu	J	India	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 06	Non Alcoholic Steatohepatitis Examined by Fast Score and Colorectal Carcinoma-A Case-Control Study
101228	Yingyun	Gong	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 06	Spingomyelin Synthase 2 Deficiency Attenuates Liver Inflammation and Fibrosis
101251	Qin	Ning	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 06	Intestinal Il-33 Exacerbates NASH by increasing Gut Microbiota-Derived Tmao Synthesis
101257	Xiwei	Yuan	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 06	Heme Oxygenase-1 Improve Mitochondrial Function and Apoptosis in Non-Alcoholic Steatohepatitis
101335	Jithin	John	India	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 06	Intrafamilial Presence of Nafld : the Genetic-Environment Link for Fibrogenesis
101346	torsten	Wuestefeld	Singapore	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 07	Liquid-Biopsy Derived Exosome Rna-Content Based Diagnostic Signature for Fatty Liver Disease
101369	Xiaofan	Wang	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 07	Hepcidin Alleviates Hepatic Steatosis Through Inhibiting Perk Signaling Pathway
101396	Qin	Ning	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 07	C-Reactive Protein and Nonalcoholic Fatty Liver Disease
101423	Lajpat	Rai	Pakistan	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 07	Assessment of Liver Fibrosis with Transient Elastography in Nafld Patients
101592	Tushar	Prabhakar	India	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 07	Exploring the Interplay of Hepatic Steatosis, Body Fat Ratio, and Hepatic Fibrosis in Mafld
101621	Erika Johanna P.	Tañada	Philippines	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 07	Impact of Renaming Nafld to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
101655	Zijian	Zhang	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 07	The Hedgehog Signal Factors and Fgfs Regulate Endothelial Cells in Non-Alcoholic Fatty Liver Disease
101825	Yunxiong	Wei	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 08	Cd36-Mediated Uptake of Oxidized Ldl Induces Ferroptosis and Dysfunction in Dntregs in Nafld
200012	Rulaiha	Taylor	United States	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 08	Effects of individual Bile Acid on Mash Development in Low Bile Acid Mouse Model
200029	Yong-An	Lee	Singapore	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 08	Therapeutic Target Identification of Mafld Through Patient Transcriptomic-Based in Vivo Rnai Screen
200098	Zhiping	Wan	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 08	Microna-411-5P Targets the Eif4g2 / Foxo3 Axis to Alleviate Lipid Deposition in Mafld
200146	Yi Qi	Yang	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 08	Ftz Inhibits the Hepatic Lipid Deposition by Tf3/Ppar Α/Ampk Signaling Pathway in Diabetes Mice
200168	Anand Krishna	Singh	India	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 08	Enhancing Liver Health in Type 2 Diabetes: Cd26 Inhibitors & Glycine Max Antioxidants Synergy
200201	Yongqiang	Xiong	China	Oral	March	28	Thursday	PM	Metabolic-Associated Fatty Liver Disease - Basic 08	The Potential Mechanism of Methotrexate induced Liver Injury in Mafld: in Silico Analysis
100082	Shijun	Ping	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 01	Vitamin E Versus Placebo in the Treatment of NASH: A Multicenter, Randomized, Double-Blind Study
100099	Yuya	Seko	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 01	The Greater Impact of Pnpl3 Polymorphism on Liver-Related

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
100732	Nicole Shu Ying	Tang	Singapore	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 04	Genetic Architecture of Lean Nafld and Paradoxical Obesity-Hepatic Steatosis Phenotypes
100756	Weixia	Sun	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 04	Prevalence and Characteristics of Lean MaflD in Patients with Diabetes: A Multicenter Study
100759	Chia Yun	Chang	Taiwan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 04	Comparing 1.5T and 3.0T Mri for Assessing Hepatic Steatosis with Proton Density Fat Fraction
100816	Yeo Wool	Kang	South Korea	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 04	Real-World Utility of Elf in A Two-Step Strategy for Detecting Fibrosis in at-Risk Nafld Patients
100832	Sang Yi	Moon	South Korea	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 05	Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver-Related Outcome
100850	Takahiro	Nishio	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 05	Impact of MASLD on Patients with Hepatocellular Carcinoma Undergoing Liver Resection
101071	Arnulf	Ferlitsch	Austria	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 05	Effects of Glp-1-Agonist Liraglutide and Semaglutide on Steatotic Liver Disease and Obesity
101106	Sarker	Sajjad	Bangladesh	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 05	Effect of Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Dm
101133	Shusuke	Kumazaki	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 05	Serum Gdf15 is A Novel Predictive Biomarker for Liver Cancer Occurrence in Patients with MASLD.
101248	Naim	Alkhouri	United States	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 05	Combination of Liverstat and Fibroscan Outperforms Fib-4 and Lsm, for MASLD Advanced Fibrosis, F3F4
101324	Michihiro	Iwaki	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 06	Impact of Single Nucleotide Polymorphisms on Long-Term Prognosis in Non-Obese MASLD
101695	Takeshi	Okanoue	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 06	Ai Diagnostic System Accurately Diagnoses Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis
101715	Asahiro	Morishita	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 06	Comprehensive Analysis of Specific Micrnas Related to therapeutic Efficacy of Pemafibrate in MASLD
101751	Sanjay	Kumar	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 06	Study to Compare the Efficacies of Vitamin E and Saroglitazar in Non Diabetic Nafld Patients
101838	Naoto	Fujiwara	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 06	Molecular MASLD Subtype to Inform Disease Progression and therapeutic Decision Making
101866	Justin R	Tse	United States	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 07	Diagnostic Performance of Ct/Mri Li-Rads V2018 in Non-Cirrhotic Steatotic Liver Disease
101883	Kyoko	Sakai	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 07	Causesspecific Mortality in Japanese Patients with Biopsy - Confirmed Nonalcoholic Fatty Liver Diseases
101908	Chymia Olivia Maurine	Jasirwan	Indonesia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 07	Unveiling Nafld: the interplay of Sefa, Elastography, and Cap
101972	Debopriyo	Ganguly	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 07	Socs1, Miox, Hnf4a: Novel Ferroptosis Genes in Nafld Pathogenesis and Fibrosis
101979	Ma, Felina Rosanna	Siray	Philippines	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 07	Semaglutide for Metabolic-Associated Fatty Liver Disease: A Meta Analysis and Systematic Review
102055	Kazuyoshi	Kon	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 08	Pilot Randomized Controlled Trial of Effects of Dapagliflozin and Vit E on MASLD with Type 2 Dm
200040	Takumi	Kawaguchi	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 08	Meta-Analysis of Luseogliflozin on Hepatic Steatosis/Fibrosis indexes in Diabetic Patients in Japan
200076	George	Lau	Hong Kong	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 08	Effects of Biejia-Ruangan Compound on Patients with Non-Alcoholic Fatty Liver Disease
200123	Hitoshi	Mochizuki	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 08	Long-Term Mass Surveys by Fibroscan Have Shown That the "Burnout Phenomenon" is Extremely Rare
200167	Feng	Xue	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 08	Hsk31679 (A Thyroid Hormone Receptor Β Agonist) in Asian Nafld with Hypercholesterolemia
200206	andi Puji	Pratiwi	Indonesia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 08	The Effects of Glp-1 Receptor Agonists in Histological Improvement of NASH: A Meta-Analysis of Rct
100092	Mehreen	Siyal	Pakistan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 09	Misoprostol for Non-Alcoholic Steatohepatitis-A Randomized Control Trial
100184	Ming-Ling	Chang	Taiwan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 09	Association of Sex and Baseline Alt Levels with Response to Pioglitazone for Sld Patients
100207	Hai-Yang	Yuan	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 09	Ai-Based Digital Pathology offers Newer insights into Lifestyle-induced Fibrosis Regression in MaflD
100222	Patricia	Valery	Australia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 09	Risk Factors for Extrahepatic Cancer in People with Non-Alcoholic Fatty Liver Disease
100235	Huai	Zhang	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 09	Exhaled Nitric Oxide for the Non-invasive Identification of Patients with Fibrotic Mash
100259	Yi	Pan	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 09	Antifibrotic Effect of Polyene Phosphatidylcholine in Chinese MaflD Patients: A Real-World Study
100277	Wei-Fan	Hsu	Taiwan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 09	The Impact of Steatotic Liver Disease on Liver-Related Events in Patients Cured of Hepatitis C Virus
100429	Xinlei	Zhang	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 10	Association Between Skeletal Muscle Strength and Chronic Kidney Disease in Patients with MaflD
100442	Thaninee	Prasoppakorn	Thailand	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 10	Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV
100445	Sabry	Abbas	Egypt	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 10	Alfaamylase Treatment and Prophylaxis of Nafld in Experimental Animals
100471	Vivian	Lee	Singapore	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 10	Ectopic Liver Fat is Associated with Diabetes and Adverse Cardiac Remodeling
100500	Jinzi J.	Wu	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 10	A Phase I Ddi Study to Evaluate the Effect of Asc42 on the Pharmacokinetics of atorvastatin
100547	Gillie Anne D.	Domingo	Philippines	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 10	Non-Alcoholic Fatty Liver Disease (Nafld) Burden Among Filipino People Living with HIV (PIHIV)
100645	Szu-Ching	Yin	Taiwan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 10	Long-Term Impact of Metabolic Dysfunction-Associated Fatty Liver Disease on Cardiovascular Diseases
100676	Prooksa	Ananchuensook	Thailand	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 11	Survey of Stigmatization Among Thai Nafld Patients, A Preliminary Result
100704	Gulnara	Aghayeva	Azerbaijan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 11	Patients with Diabetes Mellitus and Liver Diseases in Azerbaijan: Epidemiological Studies
100726	Iqbal	Taufiqurrachman	Indonesia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 11	The Role of Vitamin D Supplementation in Metabolic-Associated Fatty Liver Disease: Systematic Review
100751	Mei-Hung	Pan	Taiwan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 11	The Impact of Fatty Liver Index on HCC Among Non-Viral Hepatitis Subjects in An HBV Endemic Region
100800	Guanlin	Li	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 11	Lifestyle Modification Programme for HIV-infected Patients with Nafld: A Randomized Controlled Trial
100814	Angel Cho Kan	Ma	Hong Kong	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 11	The Effects of Lifestyle Modification interventions on Self-Efficacy Among Nafld Patients: Sr
100837	Yun Zheng	Gao	Taiwan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 11	Fibrosis-Associated Genetic Variants in Metabolic Dysfunction-Associated Steatotic Liver Disease
100859	Kamal Kant	Mangla	Denmark	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 12	Change in Fibrosis-4 index (Fib4) Over Time is Associated with Subsequent Risk of Liver Events
100865	Lok Ka	Lam	Hong Kong	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 12	Effect of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bnt162B2 Immunogenicity
100874	Yang Hyun	Baek	South Korea	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 12	Insulin Resistance in MASLD and Liver-Related Outcomes: A Nationwide, Population-Based Study
100897	Gayathri	SHIVakumar	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 12	Nfte- A Prediction Rule for Fibrosis in Metabolic-Dysfunction Associated Steatotic Liver Disease
100972	Jorg	Taubel	United Kingdom	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 12	Development of A Novel Supervised Machine Learning Algorithm Predicting MASLD in Research Volunteers
100981	Erika Johanna	Tañada	Philippines	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 12	Impact of Renaming (Nafld) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
101011	Sudhir	Maharshi	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 12	Effect of Lifestyle Measures in Normal Body Mass index Nonalcoholic Fatty Liver Disease Patients
101024	He	Yi	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 13	Low Accuracy of Noninvasivetestes for Screening for Advanced Fibrosis Among Chinese Adults with MaflD
101033	Kim	Olthoff	United States	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 13	Reducing Metabolic Syndrome Risk in Liver Transplantation: the Impact of Donor Selection
101051	Mengmeng	Hou	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 13	Prevalence and Risk Factors of MASLD and Liver Fibrosis in An Urban Chinese Population
101076	Arka	De	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 13	Validation of Agile Scores in Indian Patients with Nafld: interim Analysis of the Icon-D Study
101140	Tatia	Khachidze	Georgia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 13	Gut Microflora Composition in Patients with Non-Alcoholic FattyLiver Disease
101212	Lubna	Kamani	Pakistan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 13	Comparison of Fatty Liver index with Fibroscan in Non Alcoholic Fatty Liver Disease
101361	Jingwen	Liu	United States	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 13	Cvi-2742 is A Potential Best-in-Class Second Generation oral Liver-Targeted Thr-&Szigl; Selective Agonist
101362	Riki	Tenggara	Indonesia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 14	Liver Stiffness with Magnetic Resonance Elastography in Indonesia and Metabolic Dysfunction
101460	Amna S	Butt	Pakistan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 14	Saga of An Outlier: Lean MASLD in Urban, Population of Karachi, Pakistan
101465	Arka	De	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 14	Sequential Use of Lsm and Agile 3+ for Assessing CaclD: Indian Consortium on Nafld (Icon-D) Study
101475	Arka	De	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 14	Sequential Use of Lsm and Agile 4 for Assessing Cirrhosis: Indian Consortium on Nafld (Icon-D) Study
101492	Jeayeon	Park	South Korea	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 14	Point-of-Care Non-invasive Prediction Model for Steatotic Liver Disease: Using Bioimpedance Analysis
101493	Ling	Zhou	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 14	Frequency of MASLD and CaclD Among Adults with Steatotic Liver Disease
101500	Jie	Li	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 14	Different Minimal Alcohol Consumption in Male and Female individuals with MaflD
101501	Farhana	Kayani	Pakistan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 15	Anomogram to Predict Severity of Hepaticfibrosis by Noninvasive-Markers&Treatment Allocation inmaflD
101512	Jie	Li	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 15	Vitamin intake and the Progression of Metabolic Dysfunction-Associated Fatty Liver Disease
101513	Jie	Li	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 15	Daily Water intake is Protective Against Liver Fibrosis in MaflD
101558	Jay	toshniwal	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 15	Impact of Dietary intervention in Reversal of Fibrosis in Metabolic Associated Fatty Liver Disease
101637	Maito	Suoh	Australia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 15	Metabolic-Associated Fatty Liver Disease (MaflD) and Its Metrics for Contributions to Liver Research
101649	Akio	Moriya	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 15	Factors Predicting the Future Incidence of Fatty Liver: A Single-Center Study
101651	Ahmed	Mokhtar	Egypt	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 15	The Association Between Non-Alcoholic Fatty Liver Disease and Risk of Chronic Kidney Disease.
101654	Yuki	Hamada	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 16	NASH Complicating with T2Dm Can Be Well Controlled by Hepcidin inducer Laennec Derived from Placenta
101666	Katsutoshi	Sugimoto	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 16	The Role of Multiparametric Us in Evaluating Advanced Fibrosis in Patients with MASLD
101676	Venera	Rakhmetova	Kazakhstan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 16	Cryptogenic Liver Cirrhosis: the Key Role of Metabolic-Associated Fatty Disease Nafld
101703	A B M Shakil	Gani	Bangladesh	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 16	HigherIncidenceof DminhealthyfattyLiverpatientofbangladesh:Prompt interventioncanavertcomplication
101735	Xiaoyun	Lin	China	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 16	Modeling Disease Burden of Adolescent Nafld and NASH Based on Body Mass index
101765	Jordan	Sardjan	Indonesia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 16	Correlation Between Cap Value and Syntax Score in Patient with Coronary Artery Disease (Cad)
101777	Ryan	Herardi	Indonesia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 16	Correlations of Liver Steatosis and Fibrosis with Metabolic Parameters in Young-onset Diabetes
101784	Rajdeep	Singh	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 17	Efficacy of Saroglitazar in MASLD at 6 Months, A Single Center Observational Study
101805	Priyansh	Bhayani	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 17	Fibroscan Compared to Non-invasive Scores in Patients with Non-Alcoholic Fatty Liver Disease
101839	Bernard Johannes A.	Jimeno	Philippines	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 17	Diagnostic Accuracy of Using Anthropometric indices As Predictors of Patients with MaflD
101846	Mohammad	Hoque	Bangladesh	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 17	Role of Anthropometric indices in the Predicting of Nafld in Rural Population of Bangladesh
101863	Aung Hlaing	Bwa	Myanmar	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 17	Addition of Resveratrol to orlistat Improves Elastography Parameters in Overweight
101920	Abdullah Al	Qayyum	Bangladesh	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 17	Histological Disparity Pertaining to Insulin Resistance in Nonalcoholic Fatty Liver Disease Patients
101931	Muhammad Bilal	Saifulhaq	Indonesia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 17	Metabolic-Associated Fatty Liver Disease (MaflD) As A Risk Factor of Developing Malignant Arrhythmia
101945	Dar-in	Tai	Taiwan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 17	Comparison Between 2D-US DI Steatosis Algorithm with Fibroscan in History Proven Patients
102000	Shenoy	K T	India	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 18	Metabolic Dysfunction Associated Steatotic Liver Disease in A Cohort in Trivandrum, India
102073	Muhammad Bilal	Saifulhaq	Indonesia	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 18	Triglycerid-Glucose (Tyg) index As Novel Predictor of New onset atrial Fibrillation in MaflD Patient
200068	Muhammad Umair	Ahsan	Pakistan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 18	Efficacy and Safety of A Standarized Extract of Prunus Mume in Patients with MaflD
200071	tonguk	Teerasartipan	Thailand	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 18	Validation of Non-invasive tools for An Assessment of Liver Fibrosis in MaflD Patients with Obesity
200110	Takashi	Himoto	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 18	Clinical Characteristics of Non-Obese Patients with Nonalcoholic Fatty Liver Disease
200182	Shuntaro	Obi	Japan	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 18	Baseline Fat Characteristics As No Relation HCC Occurrence But Closely Correlation Non-HCC Malignancy
200207	wasit	Wongtrakul	Thailand	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 18	MASLD and the Risk of Mortality in Diabetic Patients: A Systematic Review and Meta-Analysis
200264	Adriana	Martinez-Cuazitl	Mexico	Oral	March	28	Thursday	AM	Metabolic-Associated Fatty Liver Disease - Clinical 18	Ferritin As A Biomarker on Weight Reduction
100475	Xiaozhe	Wang	China	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 01	Short-Term Lmwh for the Prevention of Early Tlps Dysfunction: A Randomised Controlled Trial
100561	Jeong Min	Lee	South Korea	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 01	Gradual High Power Radiofrequency Ablation with Multi-Electrodes for Small HCC: A Prospective Study
101292	Guangliang	Huang	China	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 01	Three-Dimensional Ultrasound Fusion Imaging in Precise Ablation of Hepatocellular Carcinoma
101355	Chikara	Ogawa	Japan	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 01	Evaluation of Rfa therapeutic Effect Using Workstation
101590	Ming	Xu	China	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 01	Analysis of infectious Complications after Ablation of HCC and the Impact on Long-Term Survival
101625	Maki	tobari	Japan	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 02	The Facts of Ablation for Liver Cancer in Patients Aged Ninety and Above in Our Hospital.
101832	Baoxian	Liu	China	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 02	Combined Percutaneous Rfa and Ethanol injection for HCC with Portal Vein Tumor Thrombus
101978	Tsendjav	Tsogtbaatar	Mongolia	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 02	Microwave Ablation Compared with Radiofrequency Ablation for Hepatocellular Carcinoma in Mongolia
200191	tom	Edlund	israel	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 02	A Novel Ultrasound Modality to Monitor and Visualize Ablation Area Based on Real-Time Imaging
101204	Yossi	Abu	israel	Oral	March	29				

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
101870	Baoxian	Liu	China	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 03	Percutaneous Radiofrequency Ablation for Recurrent HCC after Curative Surgery in Children
200052	Jiayao	Huang	China	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 04	Assessing and Predicting Liver Function by Elastography: 1-Year Follow-Up in HCC Ablation Patients
200064	Rong	Ding	China	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 04	Safety and Efficacy of Mva of Multiple Lesions in Multiple Lung Metastasis of Colorectal Cancer
200082	Mateo Iii	Te	Philippines	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 04	The Role of Carto in Portal Hypertension with Recurrent Upper GI Bleeding from Large Gastric Varices
200117	Xuan	Yu	China	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 04	Efficacy of Emprintm Ablation System for Perivascular Hepatocellular Carcinoma
200229	tom	Edlund	israel	Oral	March	29	Friday	AM	Ablation & Image-Guided Procedures 04	AI Based Tumor Progression Prediction Following Hepatocellular Carcinoma Ablation
100350	Hueifen	Jheng	Taiwan	Oral	March	29	Friday	AM	Artificial Intelligence 01	An AI Model for Steatosis Segmentation in Mouse Models
100853	Yayun	Ren	Singapore	Oral	March	29	Friday	AM	Artificial Intelligence 01	Impact of Sample Variability of Liver Needle Biopsies on Fibrosis Assessment
100883	Desiree	Abdurachim	Singapore	Oral	March	29	Friday	AM	Artificial Intelligence 01	Understanding Early Stage-Fibrosis in Kbi-NASH Non-Human Primate Model Using Ai Digital Pathology
100985	Stephen A.	Harrison	United States	Oral	March	29	Friday	AM	Artificial Intelligence 01	Artificial Intelligence to Measure Fibrosis Change on Liver Biopsy in the Maestro-NASH Phase 3 Trial
100989	Stephen A.	Harrison	United States	Oral	March	29	Friday	AM	Artificial Intelligence 01	Assessment of Resmetirom-Mediated Reductions in Liver Volume on Fibrosis Changes Maestro-NASH Trial
101079	Chih-Hong	Wu	Taiwan	Oral	March	29	Friday	PM	Artificial Intelligence 02	The Deep Learning of Ultrasonography in Automatic Detection and Diagnosis of Liver Tumors.
101309	Xian	Zhong	China	Oral	March	29	Friday	PM	Artificial Intelligence 02	insights into Post-Hepatectomy Liver Failure Prediction with interpretable Deep Learning Framework
101412	Linda	Chen	United States	Oral	March	29	Friday	PM	Artificial Intelligence 02	Finding Undiagnosed Hepatitis C Using A Machine Learning Algorithm: An Australian Pilot
101552	Gooyue	Guo	China	Oral	March	29	Friday	PM	Artificial Intelligence 02	Predictive Validation of Glim Criteria for Mortality in Patients with Cirrhosis: A Machine Learning
101644	Yoshihiko	Tashiro	Japan	Oral	March	29	Friday	PM	Artificial Intelligence 02	Artificial Intelligence Assisted Navigation Surgery in Laparoscopic Liver Resection
100822	Chamara K	Liyanaarachchi Lakmalaga	Singapore	Oral	March	29	Friday	PM	Artificial Intelligence 03	CaUSAI inference Data Analysis Pipeline for Identifying Proteins within Nafld/NASH Sub-Cohorts
101496	Qingyuan	Li	China	Oral	March	29	Friday	PM	Artificial Intelligence 03	Application of Transformer Model for Capsule Endoscopic Gastric Structure Recognition
101504	Marco	Distefano	Italy	Oral	March	29	Friday	PM	Artificial Intelligence 03	Practical Clinical Uses of Chat Gpt: What Hepatologists Should Know
101830	Baoxian	Liu	China	Oral	March	29	Friday	PM	Artificial Intelligence 03	Predicting Lymph Node Metastasis of Hilar Cholangiocarcinoma Based on Deep Learning Radiomics
101935	Minh H. N.	Le	Taiwan	Oral	March	29	Friday	PM	Artificial Intelligence 03	AI in Hepatitis B Screening: A Machine Learning Approach to Demographic Determinants
200056	Zhongzhi	Jia	China	Oral	March	29	Friday	PM	Artificial Intelligence 03	Deep Learning Algorithm Applied to Plain Ct Images to Identify Sma Abnormalities
200163	Steven Qh	Truong	Vietnam	Oral	March	29	Friday	PM	Artificial Intelligence 03	Automated Abdomen Ct Diagnostic Pipeline for Hepatocellular Carcinoma
101555	Hiroyasu	Sakai	Japan	Oral	March	29	Friday	PM	Basic Science & Pathology 01	The Role of the Retinoid X Receptor- α in Liver Regeneration in Mice
101810	Hiroshi	Kono	Japan	Oral	March	29	Friday	PM	Basic Science & Pathology 01	Exosomes Trigger the Production of inflammatory Cytokine by Hepatic Macrophages Via Tlr-4 Signaling
102042	Satoshi	Kawamura	Japan	Oral	March	29	Friday	PM	Basic Science & Pathology 01	Afp-Expressing Hepatocytes Function As Hepatic Stem Cells That Give Rise to Liver Cancer
100300	Naoki	Hashimoto	Japan	Oral	March	29	Friday	PM	Basic Science & Pathology 02	The Effect of Portal Diversion Model in Dog for the Liver Function
101159	Chih Chieh	Yen	Taiwan	Oral	March	29	Friday	PM	Basic Science & Pathology 02	Glutamine Promotes Liver Regeneration by Portal Tract Collagen Synthesis after Extended Hepatectomy
101633	Bangyan	Stiles	United States	Oral	March	29	Friday	PM	Basic Science & Pathology 02	Pten/Akt Signal Promotes Cholangiocyte Fate in Liver Tumorigenesis Via notch/Sox9 Signal
101822	Yukari	Shinohara	Japan	Oral	March	29	Friday	PM	Basic Science & Pathology 02	The Histological Findings with Fluorescence Microscopy for Benign Liver Tumors
101987	Mamun	Mahtab	Bangladesh	Oral	March	29	Friday	PM	Basic Science & Pathology 02	Herbs and the Live
200081	Nataliya	Razumilava	United States	Oral	March	29	Friday	PM	Basic Science & Pathology 02	Upregulated Wnt Signaling is Associated with Biliary Hyperproliferation in Biliary Cancer and Injury
200124	Takashi	Kokudo	Japan	Oral	March	29	Friday	PM	Basic Science & Pathology 02	Tumor infiltrating Immune Cells in Hepatocellular Carcinoma Differs According to the Viral Status
100255	Takeshi	Kimura	Japan	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 01	Metabolite-Based, Weight-independent Diagnostic Model for Non-Alcoholic Fatty Liver Disease (Nafld)
100355	Jing	Tang	China	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 01	Deciphering the Dynamic Immune Landscape of Primary Liver Cancer to Predict Immunotherapy Response
100831	Pei-Jer	Chen	Taiwan	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 01	HBV Virus-Host Chimera Dna Serves As A Personalized Circulating Biomarker for Residual Tumors of HCC
101176	Glenn	Oyong	Philippines	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 01	Chemoprotective Mechanisms of Skullcapflavone in Aflatoxin-induced toxicity in Thle-3 Hepatocytes
101226	Dwijio A	Sindhughosa	Indonesia	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 01	Urine Interleukin-18 (Uil-18) As A Prognostic Marker for Mortality Risk in Liver Cirrhotic
101365	Hitoshi	Mochizuki	Japan	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 01	Evaluation of Tumor Microenvironment in HCC by Tcra Gene and Transcriptome Deconvolution Analysis
101628	Akinobu	Takaki	Japan	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 01	Serum Anti-Pd-1 Autoantibody Predicts Survival of HCC Receiving atezolizumab/Bevacizumab
200244	Hongli	Liu	China	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 01	Identification of Lrg-1 in Urine As Potential Marker for Early Diagnosis of Hepatocellular Carcinoma
100298	Ken	Sato	Japan	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 02	The Significance of Plasma Xanthine Oxidoreductase Activities in A Variety of Liver Diseases
100717	Baiyi	Liu	China	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 02	Autophagy-Related Genes Promote Development of Pediatric Metabolic-Associated Fatty Liver Disease
100778	Ning	Wang	China	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 02	Exploration of the Potential Biomarker Between Covid-19 and Liver Cirrhosis-Hepatocellular Carcinoma
101553	Liye	Tao	China	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 02	Diagnosis of HBV-Associated Liver Cirrhosis and HCC Based on Lipid and Peptide Fingerprints
101865	Seul Ki	Han	South Korea	Oral	March	29	Friday	PM	Biomarkers & Biochemistry 02	Identification of Alcoholic Hepatitis-Related Genes and Mesenchymal Stem Cell Treatment Target Genes
101347	Bushra	Shahid	Pakistan	Oral	March	29	Friday	PM	Education 01	Disease Specific Awareness and Knowledge of HBV and Hcv Among Cld Patients: Experience from Pakistan
100758	Jee-Fu	Huang	Taiwan	Oral	March	29	Friday	PM	Epidemiology & Natural History 01	A Community-Centered Surveillance Program for Disease Severity Map in An Under-Resourced Region
100992	Reham	Baig	Pakistan	Oral	March	29	Friday	PM	Epidemiology & Natural History 01	The Prevalence of Hepatitis B and Hepatitis C Among Police officers of Rawalpindi, Pakistan
101089	Adela	Turcanu	Moldova	Oral	March	29	Friday	PM	Epidemiology & Natural History 01	Earlier Liver Cirrhosis onset in Intrafamilial Hepatitis Delta Virus Transmission in Moldova
101400	Jack	Stone	United Kingdom	Oral	March	29	Friday	PM	Epidemiology & Natural History 01	Modelling the Impact of Vaccination on HBV Transmission and Progress to Elimination in Punjab, India
100342	Mingfang	Ji	China	Oral	March	29	Friday	PM	Epidemiology & Natural History 02	A 10-Year Assessment of A Population-Based Prospective Liver Cancer Screening Project in Zhongshan
100492	Song Huy	Nguyen Dinh	Vietnam	Oral	March	29	Friday	PM	Epidemiology & Natural History 02	Hepatocellular Carcinoma at Liver Tumor Department, Cho Ray Hospital: Cancer Registry 2010-2022
100502	Saltanat	Maharramzade	Azerbaijan	Oral	March	29	Friday	PM	Epidemiology & Natural History 02	Epidemiology of HCC in Patients with Viral Hepatitis
100523	Na	Wu	China	Oral	March	29	Friday	PM	Epidemiology & Natural History 02	Clinical and Immune Feature of Anti-Mda5 Dermatomyositis Patients with Covid-19 During Omicron Wave
100650	Xiaoxiao	Wang	China	Oral	March	29	Friday	PM	Epidemiology & Natural History 02	Trends of the Mortality of Cirrhosis in China: An Analysis of the China Death Surveillance Database
100829	Jumpei	Okamura	Japan	Oral	March	29	Friday	PM	Epidemiology & Natural History 02	The Role of Nurses and Clinical Engineers in Percutaneous Locoregional Treatment for Liver Cancer
100922	Tesfa S	Alameh	United Kingdom	Oral	March	29	Friday	PM	Epidemiology & Natural History 02	Changes in the Prevalence of Hepatitis B and C Viral Infections in Sindh Province, Pakistan
101030	Takashi	Iizumi	Japan	Oral	March	29	Friday	PM	Epidemiology & Natural History 03	Prognostic Impact of Solitary Large (≥ 5 Cm) Hepatocellular Carcinoma Treated with Proton Beam
101334	Yumna	Shahid	Pakistan	Oral	March	29	Friday	PM	Epidemiology & Natural History 03	Hepatitis A Among Adult Patients Presenting with Acute Hepatitis: A Changing Epidemiological Trend
101407	Anne-Sofie	Seidelin	Danmark	Oral	March	29	Friday	PM	Epidemiology & Natural History 03	Genetic Variation in Sic39A8 and Risk of Hepatocellular Carcinoma in the Danish General Population
101408	Helene	Gellert-Kristensen	Denmark	Oral	March	29	Friday	PM	Epidemiology & Natural History 03	Telomere Length and Risk of Cirrhosis and Liver Cancer in the Danish General Population
101439	Adelina A	Artenie	UK	Oral	March	29	Friday	PM	Epidemiology & Natural History 03	Global, Regional, and Country-Level Estimates of New HCV Infections attributed to injection Drug Use
101632	Beatrice J	Tiangco	Philippines	Oral	March	29	Friday	PM	Epidemiology & Natural History 04	The Creation of A Hepatocellular Cancer (HCC) Registry in A Low-to-Middle income Country (Lmic)
101755	Adelina	Artenie	United Kingdom	Oral	March	29	Friday	PM	Epidemiology & Natural History 04	Global, Regional, and Country-Level Estimates of New HCV Infections attributed to injection Drug Use
101768	Yanglan	He	China	Oral	March	29	Friday	PM	Epidemiology & Natural History 04	Risk Factors for Short Outcomes after Egvb: A Follow-Up Study of 243 Elder Cirrhotic Patients
101772	Yunus Emre	Dalkilic	Turkey	Oral	March	29	Friday	PM	Epidemiology & Natural History 04	Shifting Trends in Indications and Diagnoses of Liver Biopsies Over Two-Decades
101842	Sri	Yanti	Indonesia	Oral	March	29	Friday	PM	Epidemiology & Natural History 04	The Phylogenetic and Geospatial Approach for Hepatitis B Virus Genotype Distribution in Indonesia
100166	tongguo	Miao	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 01	Targeting Cdk5/Pak1 Attenuates Lipid Overload-induced HCC Via Suppressing Lysosomal Stress
100245	Masako	Mishima	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 01	Tert Upregulation Promotes Cell Growth Via Degradation of P21 and Enhances Hepatocarcinogenesis
100448	Xin	Hu	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 01	Integrated Multiomics Reveal Clinical Correlation Between Circrpt2 and Liver Transplantation for HCC
100858	Ming-Lun	Yeh	Taiwan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 01	Intra-Tumoral Microbiome Promotes Hepatoma Cell Proliferation and is Associated with Prognosis
100943	Haruhiko	Takeda	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 02	Whole-Genome Sequencing-Based Mutational Analysis on Hypovascular Small Hepatocellular Carcinoma.
101137	Naoko	Ohtani	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 02	Low-Speed Regular Exercise Reduces HCC Development by Muscle Pgc1 α -Mediated Kynurenine Degradation
101473	Janina Ee	Tirnitz-Parker	Australia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 02	Development of Precision-Bioprinted Patient-Derived Organoids for High-Throughput Drug Screening.
200046	Vikas	Kumar	India	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 02	Alpha-Mangostin Nanoparticles Exerts Hepatocellular Carcinoma Via Alteration of P13K/Akt Pathway
100043	Ya-Ling	Yang	Taiwan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 03	Mir-29A Restrains the Development of Hepatocellular Carcinoma Via Targeting Mybl2
100084	Xiyao	Chen	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 03	Epigenetic Regulation of the Znf384/Nol9 Axis in Hepatocellular Carcinoma
100124	Koji	Fujita	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 03	Cabozantinib Inhibits Tumor Growth of Lenvatinib-Resistant Hepatoma Cells in Vitro and in Vivo
100156	Beng	Yang	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 03	Irgm is A Novel Regulator of Pd-L1 Via Promoting S6K1/Ybx1 Axis in Hepatocellular Carcinoma
100179	Amr	Amin	UAE	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 03	Novel Biomolecule Potentiates Classic therapeutic Protocol Against Hepatocellular Carcinoma
100219	Hao	Cui	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 03	A Novel Bile Acid-Related Lncrna Signature for Predicting Prognosis and Treatment Response in HCC
100225	Hui	Wang	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 03	Inhibition of Cdk4/6 and Xpo1 induces Senescence with Acquired Vulnerability to Crbn-Based Protacs
100260	Baek Gyu	Jun	South Korea	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 04	Clinical Significance of Cytokine Change in Hepatocellular Carcinoma after RadioTherapy
100273	Subburaj	Ilangumaran	Canada	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 04	Socs1 Tumor Suppressor Sensitizes Hepatocellular Carcinoma Cells to Oxidative Stress
100297	Hiéu	Hiéu	Vietnam	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 04	Research on Image Characteristics of Primovist – Mri in Diagnosis Hepatocellular Carcinoma
100302	Chaiyaboot	Ariyachet	Thailand	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 04	Microrna-885-5P As A Master Regulator in Cell Cycle Progression of HCC Cells
100343	Guang-Zhi	Jin	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 04	A Peptide Encoded Lincrna Promotes Hepatocellular Carcinoma Progression
100406	atsushi	ono	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 04	Peripheral T Cell Subsets As A Potential Biomarker for Immunotherapy in Hepatocellular Carcinoma
100408	Yosuke	Murata	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 04	Molecular Changes of Circulating Tumor Cells in HCC Patients Receiving atezolizumab Plus Bevacizumab
100449	Xin	Hu	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 05	Multiple Omics Revealed the Clinical Correlation Between Circrpt2 and Liver Transplantation for HCC
100513	Siyu	Chen	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 05	Mitochondria-Targeted Icaritin induces Immunogenic Cell Death in Hepatocellular Carcinoma
100586	Shigeharu	Nakano	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 05	Msh2 Suppresses HCC Progression Via Regulating the Cell Cycle in Response to Dna Damage
100648	Limmeng	Zhang	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 05	Targeting Xpo1 inhibits Proliferation of Hepatocellular Carcinoma Cells by Disrupting Redox Balance
100694	Xuguang	Zhang	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 05	Luseogliflozin Attenuates Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma in Diabetic Mice
100696	Sunbin	Ling	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 05	Integrated Multiomic Analysis in HCC Beyond the Milan Criteria Undergoing Liver Transplantation
100712	Dongbo	Chen	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 05	Sirpa Overexpression induces Aicd of Tumor-infiltrating T Lymphocytes in Hepatocellular Carcinoma
100742	Agustiniingsih	Agustiniingsih	Indonesia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 06	The Effect of Src1 Inhibitors in Hepatitis B-Related Liver Cancer
100755	Ming	Liu	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 06	Identification of Developmental Heterogeneity and Potential therapeutic Targets in HCC
100760	Yao	Yang	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 06	Prognosis Prediction Based on B Cell Markers Through Single-Cell and Bulk Rna-Seq Analysis for HCC
100823	Sisi	Zhang	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 06	the Urea Cycle Enzyme Cps1 inhibits the Metastasis of HCC Through Recruiting Cd8+T Cells
100856	Hung-Wen	Tsai	Taiwan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 06	Image Analysis Highlights Distinct Fibrosis Patterns in Combined Hepatocellular-Cholangiocarcinoma
100864	Takuto	Nosaka	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 06	HCC-Derived Gm-Csf induces Leukotriene Production in Cd163+ Tams Contributing to Cancer Progression
100892	Korri	El Khobar	Indonesia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 06	Inhibition of Sfk and Its Effect on Cancer Stem Cell Markers Expression in HBV-Related HCC
100900	Shaoping	She	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 07	Psmg Suppresses HCC Progression Through inhibiting Macrophage M2 Polarization Via P13K/Akt Pathway
101145	inah Marie C.	Aquino	Philippines	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 07	Investigation on the Tumor Suppressor Role of Mir-3185 in Hepatocellular Carcinoma
101245	Na	Qiang	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 07	Megf6 Suppresses Muscle Differentiation and increases Tumor Proliferation in Lenvatinib-Treated HCC
101272	Daniel Wai-Hung	Ho	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 07	Disparity Landscapes of HBV integration in Liver Cancer: Mechanistic and Functional Implications
101384	Ha Thi	Nguyen	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 07	Unique Pattern of Cell-Cell Interaction in Cytoglobin Knock-Out Mice Promoting Liver Tumor formation

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
101534	Naoki	Yokota	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 08	Development of the Liver Tumor-Bearing Rat Model with Dual Optical Imaging
101554	Meng	Lu	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 08	Rab14 Potentiates Cd147 Cytoplasm Translocation to Promote HCC Metastasis by Nme1-Mediated Pathway
101564	Ka Hei	Lam	Hong Kong	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 08	Crispr Screen for Kinase Potentiating T Cell-Mediated Cytotoxicity in Hepatocellular Carcinoma
101631	Xing	Jia	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 08	A Precision Therapy Targeting Replication Stress in Hepatocellular Carcinoma by Wee1 Inhibition
101710	Kyoko	Oura	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 08	Mir-485-3P As A Predictive Biomarker in atezo/Beva Therapy and Analysis of Plas3/Stat3/Vegf Signal
101721	Necati	ormeci	Turkey	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 08	In Vitro therapeutic Effects of Bosentan and Obeticolic Acid on Hepatocellular Carcinoma Cells
101746	Ying	Zhang	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Basic 08	Transcriptome Sequencing was Used to Analyze the Mechanism of Cenpf Involved in Regulation of HCC
101843	Takayuki	Kogure	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Basic 09	Microna-491 Ameliorates Lenvatinib Resistance in Hepatocellular Carcinoma Cells
101857	Ren-Yu	Zhang	China	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Basic 09	Ube2S Promotes Tumor Glycolysis by Enhancing K11-Linkage Ubiquitination at Lysine 171 and 196 of Vhl
101876	Balsubramanian	Vairappan	India	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Basic 09	Nimbolide Reduces Tumor Growth and Metastasis by Regulating Mir145 Expression in Liver Cancer
101888	George	Lau	Hong Kong	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Basic 09	Fan Hinders Metastasis and Mitigates Inflammation-Related Emt by Targeting Foxm1-Adam17 Axis in HCC
101980	Hoang	Truong	Vietnam	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Basic 09	Cancer Cell Produce Liver Metastasis Via Intracellular Gap Formation in Sinusoidal Endothelial Cells
102049	Priyanka	Shenoy	India	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Basic 09	Determinants of Hepatocellular Carcinoma in Alcohol Liver Disease Patients
200006	Katsuya	toshida	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Basic 09	The Impact of Tigar on Tumor Microenvironment and Resistance to Ferroptosis in HCC
200143	Danjuan	Lu	China	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Basic 09	Double Knockout of P53/Pten Induced An HCC Mouse Model Shared A Similar Transcriptome to Human HCC
100045	Hongping	Xia	Singapore	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 01	Immunophenotyping and Tumor Microenvironments of HBV-Positive and Negative Hepatocellular Carcinoma
100080	Takamasa	Ohki	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 01	Prognostic Impact of Cyber-Knife As Part of Multidisciplinary Treatment in Hepatocellular Carcinoma
100244	Mi Na	Kim	South Korea	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 01	Similar Recurrence after Curative Treatment of HBV-Related HCC, Regardless of HBV Replication
100261	Baek Gyu	Jun	South Korea	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 01	The Impact of High Body Mass Index on Hepatocellular Carcinoma in Chronic Liver Disease
100371	Tengfei	Si	United Kingdom	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 01	Identifying Optimal Candidates for Haic Over Sorafenib: A Systematic Review and Meta-Analysis
100416	Da-Liang	Ou	Taiwan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 02	Integrative Translational Research to Study T Cell Exhaustion in Hepatocellular Carcinoma (HCC)
100450	Wei-Lun	Liou	Singapore	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 02	Asap Algorithm Demonstrates High Sensitivity for HCC Surveillance – A Prospective Study
100460	Masayuki	Ueno	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 02	A Multi-Center Study on Predictors of Primary Resistance to atezolizumab Plus Bevacizumab Therapy
100634	Jie	Yu	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 02	Association Between Post-Ablation Fever and Prognosis in Initial Hepatocellular Carcinoma
100640	Makoto	Moriyama	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 02	Assessment of Cases with Prolonged Elevation of Tumor Markers without Detectable HCC Recurrence
100782	Ju Dong	Yang	United States	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 03	Immune Checkpoint Inhibitors for Downstaging HCC Before Liver Transplantation: A Systematic Review
100852	Jonathan	Abdelmalak	Australia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 03	Improved Survival in Bcl2 0/A HCC with Resection Vs Ablation: A Propensity-Matched Multicentre Study
101099	Yoshinari	Asaoka	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 03	Chronological Changes in Clinical Characteristics of HCC Patients Undergoing Systemic Therapy
101101	Chien-Hung	Chen	Taiwan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 03	Urban Rural Disparities at Presentation and Overall Survival of Hepatocellular Carcinoma in Taiwan
101126	Hasmik	Ghazinyan	Armenia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 03	Molecular Characterization of Hepatocellular Carcinoma in Armenia, 2019-2020: initial Observations
101199	Kaoru	Tsuchiya	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 04	Clinical Outcome of atezolizumab Plus Bevacizumab in HCC with Major Portal Vein Invasion
101242	Keisuke	Koroki	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 04	Impact of Complete Tumor Control, "So Called Cancer Free", in Patients with Advanced-Stage HCC
101243	Teppe	Akatsuka	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 04	Systemic therapies for Patients with Intermediate Stage HCC and the Evolution of the Prognosis
101341	Keishi	Ouchi	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 04	Analysis of atezolizumab Antidrug Antibody in HCC Patients Treated with atezolizumab and Bevacizumab
101476	Rui	Hu	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 04	Screening of Prognostic Markers and Predictive Analysis of Potential Traditional Chinese Medicine
101519	Takeshi	Hatanaka	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 05	Increased Spleen Volume During atezolizumab and Bevacizumab: Predictive Factors and Clinical Outcome
101548	Sherin	Thomas	India	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 05	Diagnostic Assessment of Pivka-ii in the Detection of Hepatocellular Carcinoma in Indian Patients
101561	Akira	Nishio	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 05	Single-Cell Profiling of the Circulating Immune Cell Predicts the Immunotherapy for HCC
101568	Yuji	Iimuro	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 05	Impact of Genetic Discrimination Between Mc and Im on the Prognosis of Recurrent HCC
101578	Takeshi	Hatanaka	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 05	Conversion Therapy for Unresectable HCC in 944 Patients Following atezolizumab and Bevacizumab
101609	Lihua	Yu	China	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 06	Constructing Immune Classification to Predict Clinical Response of HBV-HCC after Tace Treatment
101619	Chien-Huai	Chuang	Taiwan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 06	Prescription Patterns of Sorafenib and the Following Salvage Treatment for Advanced HCC in Taiwan
101696	Satoshi	Kobayashi	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 06	Progression Pattern and Survival in Patients Received atezolizumab + Bevacizumab for Advanced HCC
101762	Xiaoli	Liu	China	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 06	Increased Pd-1+Tigit+ Tim-3+ in Peripheral Circulating Cells Predict Poor Prognosis of HCC Patients
101841	Shinsuke	Uchikawa	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 06	The Efficacy and Safety of Durvalumab + Tremelimumab for Unresectable Hepatocellular Carcinoma
101907	Haiyi	Long	China	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 07	Liver Regeneration Following Partial Hepatectomy in Hepatocellular Carcinoma: not only Size Matters
101924	Chyntia Olivia Maurine	Jasirwan	Indonesia	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 07	Decoding HCC Survival: A Comparative Analysis of Early Vs. Late-onset Cases
101977	Yutaka	Yasui	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 07	Utility of Lens Culinaris Agglutinin-Reactive Afp (Afp-L3) in atezolizumab Plus Bevacizumab Therapy
101981	Sikai	Qiu	China	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 07	Trends and forecast Mortality of Liver Cancer to 2040 in the United States: A Population-Based Study
102061	issei	Saeki	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 07	Impact of Methylated Sept9 Liquid Biopsy Test As A Prognostic Biomarker in Hepatocellular Carcinoma
200062	Zhicheng	Jin	China	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 08	Icis and Anti-Vegf Antibody/Tkis with Or without Tace As First-Line Treatment for Advanced HCC
200276	Nobuhito	Taniki	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 08	Safety and Efficacy of Microwave Ablation for Child B Early Stage Hepatocellular Carcinoma
200279	George	Lau	Hong Kong	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 08	Four-Year Overall Survival from the Himalaya Study in Unresectable Hepatocellular Carcinoma
200280	George	Lau	Hong Kong	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 08	Outcomes by Occurrence of Immune-Mediated Adverse Events in Himalaya Study in Unresectable HCC
200281	George	Lau	Hong Kong	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 08	Temporal Patterns of Immune-Mediated Adverse Events in Himalaya Study in Unresectable HCC
100070	Jiaxin	Han	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 09	Impact of Nafid on the Efficacy of Immunotherapy for Chb-Related Hepatocellular Carcinoma
100103	Xiaoxin	Wu	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 09	An online Risk Stratification Model for Predicting Survival Duration of Older Patients with HCC
100111	Yasunori	Minami	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 09	Lung Metastasis from HCC is More Powerful in Predicting Brain Metastasis Rather Than Bone Metastasis
100112	Yasunori	Minami	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 09	Fatal Ards after A Single Dose of atz/Bv for HCC, Autopsy Findings: A Case Report
100165	tongguo	Miao	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 09	Monocyte to High Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Mafld-Related HCC
100168	Jeayeon	Park	South Korea	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 09	Comparison of atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma with Pvt
100171	Shizhong	Yang	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 09	Efficacy and Safety of MultiTherapy for Locally Advanced, Unresectable Hepatocellular Carcinoma
100234	Michiko	Yamada	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 10	Experience of Tremelimumab Plus Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
100291	Keisuke	Hamamura	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 10	Estimating the Appropriate Observation Period after Hepatitis C Virus Eradication
100357	Hiroaki	Nagamatsu	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 10	New Fp Therapy for Long-Term Prognosis in Patients with Advanced Hepatocellular Carcinoma
100359	Hong	Peng	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 10	A Predictive Model to Assess Recurrence after Hepatectomy for Hepatocellular Carcinoma
100390	Chun-Ming	Hong	Taiwan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 10	No Impact of Sarcopenia in Prognosis of Transarterial Chemoembolization for Hepatocellular Carcinoma
100422	Yoshinori	Takeda	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 10	Time-to-interventional Failure in Hepatocellular Carcinoma
100435	Hideki	Iwamoto	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 10	Usefulness of A Novel Microcatheter Insertable Port Remap/System-I for Transarterial Therapy of HCC
100472	Ka Shing	Cheung	Hong Kong	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 11	Association Between Sglt-2 Inhibitors and Death from Hepato-Bilio-Pancreatic Cancer
100526	Kazufumi	Kobayashi	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 11	Differences in Hemodynamics of Lenvatinib Based on Liver Function for Hepatocellular Carcinoma
100529	Tasuku	Nakabori	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 11	Combining Selective Locoregional Treatment with atezolizumab Plus Bevacizumab for Unresectable HCC
100536	Callista Vania	Raharjo	Australia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 11	A Tertiary Hospital Experience of atezolizumab & Bevacizumab for Advanced Hepatocellular Carcinoma
100572	Jumpei	Okamura	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 11	Prediction of Prognosis in atezolizumab Plus Bevacizumab for Unresectable HCC
100609	Alfatea Pintari	Rahmi	Indonesia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 11	Serum Insulin Growth Factor-1 As A Disease Course Predictor in Hepatocellular Carcinoma Patients
100659	Thinesh	Krishnamoorthy	Singapore	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 11	Mrna Based HBV-Specific Tcr T-Cell Infusions Can Induce Broad HBV T-Cell Response in HBV-Related HCC
100684	I-Cheng	Lee	Taiwan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 12	M2Bpgi Correlated with Immune Biomarkers and Stratified Risk of Hepatocellular Carcinoma Recurrence
100708	Vaneet	Jearth	India	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 12	Ceus for Differentiation of Benign Vs Malignant Pvt in HCC – A Systematic Review with Meta-Analysis
100746	Hui Yan Agnes	Ho	Hong Kong	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 12	Nonselective β-Blocker Use Does not Impact on Mortality in Patients with Hepatocellular Carcinoma
100797	Shukui	Qin	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 12	First-Line Lenvatinib ± Pembrolizumab for Advanced Hepatocellular Carcinoma: Leap-002 China Subgroup
100878	Takumi	Yanai	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 12	Rfa of Progressive HCC after Introduction of Chemo Therapy, May Extend Life Prognosis.
100895	Jing	Chen	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 12	Serum Hcbab Level Can Predict the Occurrence of Hepatitis B Related Hepatocellular Carcinoma.
100937	Nitish	Patwardhan	India	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 12	Albi Vs Ctp- Predictor of Post-Tace Hepatic Decompensation in Intermediate Stage HCC
100971	Resha Dermawansyah	Rusman	Indonesia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 13	Comparison of Alpha-Fetoprotein with Viral & Non-Viral Etiology in Hepatocellular Carcinoma Patients
101023	Aditya	Verma	India	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 13	2D- Shear Wave Elastography of Tumor - A Novel Predictor of Response to Tace in Patients with HCC
101027	Zahabia	Sohail	Pakistan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 13	The Distribution of Bcl2 2022 Stages Among Patients with Hepatocellular Carcinoma
101041	Takeshi	Hatanaka	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 13	A Comparison of Surgical Resection and Rfa for Early-Stage HCC Patients with Child-Pugh Class B
101078	Mohamed	Abdel-Samiee	Egypt	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 13	Evaluation of Circular Rna Smarca5 As A Novel Biomarker for Hepatocellular Carcinoma
101142	Bobin	Hu	China	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 14	Integrative Characteristics of HBV -HCC after Nucs Long-Term Antiviral Therapy
101185	A.Kadir	Dokmeci	Turkey	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 14	The Causes of HCC in Turkey
101187	Masashi	Ninomiya	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 14	The Factors Contributing to Prolonged Survival in the Intermediate Stage HCC Using Survival Model
101314	Takuya	Yonemoto	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 14	Safety of Stride Regimen for Advanced Hepatocellular Carcinoma and Its Optimal Management
101322	Nobuhito	Taniki	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 14	Exploratory Effectiveness of atezolizumab + Bevacizumab Against UHCC Beyond Radiological Progression
101330	Teiji	Kuzuya	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 14	Significance of Complete Response in atezolizumab-Bevacizumab for Advanced Hepatocellular Carcinoma
101333	Devika	Madhu	India	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 14	India Pabulum Index Predicts Short Term Mortality in Patients with HCC : A Prospective Study
101338	Gulzar	Khan	Pakistan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 15	Clinical Characteristics and Barcelona Clinic Liver Cancer Staging in Patient with HCC.
101371	Sidharth	Harindranath	India	Or						

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
101824	Masashi	Ninomiya	Japan	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 17	Development of A New Model to Predict Survival Duration with HCC Patients in BclC C Stage
101853	Xiaozhou	Zhou	China	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 17	Biomarker Discovery for HCC Detection and Prognosis Via Plasma Cfdna Methylome Profiling
101867	George	Lau	Hong Kong	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 17	Risk of HCC Occurrence after Antiviral Therapy for Chc: A Systematic Review and Meta-Analysis
101911	Liyan	Dong	China	Oral	March	29	Friday	PM	Hepatocellular Carcinoma – Clinical 17	Association of Abo Blood Groups and Rhesus Factor with Primary Liver Cancer in Cirrhosis
101921	Soe Thiha	Maung	Thailand	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 18	Non-Contrast Abbreviated Mri for the Detection of Hepatocellular Carcinoma
101966	Long	Cheng	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 18	Effectiveness and tolerability of Camrelizumab Therapy for Elderly Patients with Advanced HCC
101984	Ken	Kageyama	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 18	Factors Enhancing Local Control of Tace Recommended in BclC Strategy 2022-Update for BclC-0&A HCC
102028	Muhammad Bilal	Saifulhaq	Indonesia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 18	Insulin Growth Factor-1 Level As A Disease Course Predictor in Hepatocellular Carcinoma Patients
102044	Masatsugu	ishii	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 18	Efficacy and Safety of Arterial Infusion ChemoTherapy in Patients with Child–Pugh Class B
102050	Wonseok	Kang	South Korea	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 18	Systemic Therapy in HCC Patients with Marginal Liver Function: atezolizumab/Bevacizumab Vs Sorafenib
102077	Shingo	Shimada	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 18	Liver Resection for Hepatocellular Carcinoma Focused on the Fourth Branch of the Portal Vein
102081	Takuma	Okada	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 19	The Prediction Models for Post-Hepatectomy Liver Failure Based on the Type IV Collagen 7S Domain
102087	Takatsugu	Matsumoto	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 19	Outcomes of Surgical Resection of Hepatocellular Carcinoma with Non-Alcoholic Fatty Liver Disease
200007	Jiayao	Huang	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 19	2D-Swe in HCC: Accessing and Predicting Liver Function
200009	Jiayao	Huang	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 19	Assessment of Liver Function by 2D-Swe in HCC at Different HBV Infection Status
200017	Yuichi	Goto	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 19	Conversion Surgery for Hepatocellular Carcinoma; Relationship Between the Necrosis Rate and Outcome
200067	Hikmet	Akkz	Turkey	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 19	Cancer-Associated Fibroblasts (Cafs) Promote the Growth of HCC Cells Through Expressing Activin-A
102010	Long	Cheng	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 20	Effectiveness and tolerability of Camrelizumab Therapy for Elderly Patients with Advanced HCC
200074	Chrisandi	Rizqiansyah	Indonesia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 20	Lenvatinib Combination Therapy Vs Monotherapy in Unresectable Hepatocellular Carcinoma
200095	Norifumi	iseda	Japan	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 20	Impact of Albumin-Lymphocyte-Platelet-Crp index on Outcome in Hepatocellular Carcinoma
200121	Yu	Cheng	China	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 20	Laparoscopic Drainage Basin Hepatectomy Based on Cone Unit
200275	Muhammad Bilal	Saifulhaq	Indonesia	Oral	March	29	Friday	AM	Hepatocellular Carcinoma – Clinical 20	Ici and Systemic Therapy Comparison on Progression-Free Survival of Advanced HCC:Metaanalysis of Rct
100114	Ping	Liang	China	Oral	March	29	Friday	PM	Imaging & Diagnosis 01	Deep Learning Model Based on Ceus Improves Diagnostic Ability on Differentiating HCC and Icc
100321	Yoshiko	Nakamura	Japan	Oral	March	29	Friday	PM	Imaging & Diagnosis 01	Ultrasound-Derived Fat Fraction (Udff) for Quantification of Steatosis with Reference to Biopsy
100398	Rong	Fan	China	Oral	March	29	Friday	PM	Imaging & Diagnosis 01	A New Stage in the Transformation from Cirrhosis to Hepatocellular Carcinoma Defined by Alarm Model
100828	Qian	Zhang	China	Oral	March	29	Friday	PM	Imaging & Diagnosis 01	Reduced Glymphatic System Activity induces Elevated Gaba Level in Hepatic Encephalopathy Patients
101295	Tamami	Abe	Japan	Oral	March	29	Friday	PM	Imaging & Diagnosis 01	Development of A New Hepaticumor Diagnostic Method Using Sonazoid Contrast-Enhanced Ultrasonography
101886	George	Lau	Hong Kong	Oral	March	29	Friday	PM	Imaging & Diagnosis 01	Multiparametric Mri-Based Radiomics Nomogram Predicts the Recurrence of HCC
100059	Chileka	Chiyanka	Hong Kong	Oral	March	29	Friday	PM	Imaging & Diagnosis 02	Mri Iron-Corrected T1 Mapping May Have Utility to Monitor NASH Following Weight Loss interventions
100984	Zilong	Wang	China	Oral	March	29	Friday	PM	Imaging & Diagnosis 02	Myosteatosis and Sarcopenic Obesity independently Predict Mortality of Patients with Pbc
101189	Biswa R	Patra	India	Oral	March	29	Friday	PM	Imaging & Diagnosis 02	Eus Multi-Action Liver Biopsy Better Than Percutaneous in Adequacy and Pain with Equal Safety
101340	Akash	Shukla	India	Oral	March	29	Friday	PM	Imaging & Diagnosis 02	Exploring the Utility of Eus in Budd-Chiari Syndrome : A Multicenter Multiobserver Prospective Study
101458	Hafiz Mughees	ather	Pakistan	Oral	March	29	Friday	PM	Imaging & Diagnosis 02	Retrospective Analysis of therapeutic Ercp in A Tertiary Care Hospital in Faisalabad
101556	Manxia	Lin	China	Oral	March	29	Friday	PM	Imaging & Diagnosis 02	Stiffness onswc As Potential Microenvironment Biomarker for Predicting Recurrence in HBV-Related HCC
101589	Ming	Xu	China	Oral	March	29	Friday	PM	Imaging & Diagnosis 02	Diagnostic and Prognostic Ability of Ceus and Biomarkers in Hepatocellular Carcinoma Subtypes
101915	Naglaa	Abd El-Latif	Egypt	Oral	March	29	Friday	PM	Imaging & Diagnosis 02	A Tricky Case of Pleositis Hepatis : Case Report
200153	Dongdong	Jin	China	Oral	March	29	Friday	PM	Imaging & Diagnosis 02	Differentiating Renal Urothelial Carcinoma and Endophytic Renal Cell Carcinoma Using Us and Ceus
100478	Xiaoze	Wang	China	Oral	March	29	Friday	PM	iPS (induced pluripotent stem) Cells 01	Msc-Derived Extracellular Vesicles Alleviate ischemia Liver Injury Via inhibiting Nets formation
101693	Yosuke	Asami	Japan	Oral	March	29	Friday	PM	Medical Engineering 01	Microwave Ablation (Mwa) Antenna Emprint Visualization innovation
200184	Wenxin	Wu	China	Oral	March	29	Friday	PM	Medical Engineering 02	Sonodynamic Therapy Improves Cancer Immunotherapy after insufficient Radiofrequency Ablation
200122	Koshi	Kunimoto	United States	Oral	March	29	Friday	PM	Medical Technology 01	InvitrogenVivofectamine Lnp Library for in Vivo Rna Delivery to Liver from Mouse to Nhp
200278	Joseph D	Braman	United States	Oral	March	29	Friday	PM	Medical Technology 01	Overlapping and Power Ramping Ablation Zone Techniques Using the Emprint Ablation System
101059	Zihao	Huang	Hong Kong	Oral	March	29	Friday	PM	Medical Technology 02	Refining Liver Fibrosis Assessment: Palm-Sized Transient Elastography Guided with B-Mode Imaging
101060	Soe Thiha	Maung	Myanmar	Oral	March	29	Friday	PM	Medical Technology 02	Telemedicine for Hepatology Consultations in Myanmar: A Single Centre Experience
101067	Anbang	Chen	China	Oral	March	29	Friday	PM	Medical Technology 02	Intravascular Ultrasound-Guided Direct Portal Vein Puncture for Tips: A Proof-of-Concept Study
101288	Meidai	Kasai	Japan	Oral	March	29	Friday	PM	Medical Technology 02	Augmented Reality Navigation for Laparoscopic Liver Surgery: A Comparison with Icg Fluorescence
101329	Arun	Prabhakaran	India	Oral	March	29	Friday	PM	Medical Technology 02	An Equivalence Design to Compare Two Non-invasive tools to Predict Esophageal Varices in Cirrhosis
101891	Chuyang	Zhang	China	Oral	March	29	Friday	PM	Medical Technology 02	Mimic Nanovesicle with Enhanced Pd-1 Expression induce Immunomodulation for Immunotherapy after Irfa
100725	Shinichiro	Yamada	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 01	New oncological Resectability of CrIm and Multidisciplinary Treatment Strategy
100949	Fan	Mu	China	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 01	Flna Cargo in Exosome Promote Pre-Metastatic Niche formation in Intrahepatic Cholangiocarcinoma
101264	Etsushi	Kawamura	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 01	Exploring Genes Involved in Proliferation of Intrahepatic Cholangiocarcinoma Using Clinical Samples
101582	Shyna Zhuoying	Gunalan	Singapore	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 01	Prevalence of Chronic Liver Disease in Cholangiocarcinoma - A Single Arm Metaanalysis of 113 Studies
101873	Huanling	Guo	China	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 01	A Nanodrug Designed to Maintain Antitumor Immunity in Liver Metastases after Radiofrequency Ablation
101970	Yuhi	Shimura	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 02	The Efficacy of total Tumor Volume in Patients with Colorectal Liver Metastases
102030	toru	Beppu	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 02	High-Risk CrIm Can Provide Excellent Survival Through Multidisciplinary Treatment including Ablation
102045	Masatsugu	ishii	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 02	Hepatic Arterial Infusion is Effective in Patients with Unresectable Colorectal Liver Metastases
102083	Satoshi	Eguchi	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 02	Il-33 Facilitates Icca Progression by increasing the Secretion of Il-6 from Cafs
200261	Yukihiro	Koike	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 02	Radio-Frequency Ablation of Hepatic Metastases from Sarcoma
100522	Koji	Uchino	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 03	Hepatic Lymphoma Diagnosed by Liver Biopsy: Clinicopathological Features of 15 Japanese Patients
100532	Shiori	Kaji	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 03	A Case of Spontaneous Rupture of A Giant Hepatic Hemangioma
100564	Mochamad	Affudin	Indonesia	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 03	The ChemoTherapy Response Prediction Based on Radiomics Method in Liver Metastasis: A Meta-Analysis
100987	Rene John	Febro	Philippines	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 03	Liver-Directed Microwave Ablation of Oligometastatic Renal Cell Carcinoma in A Cirrhotic Patient
101095	Masao	Nakajima	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 03	Neoadjuvant Folfoxiri Therapy for Patients with Colorectal Liver Metastasis
101434	Shann	Long	Singapore	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 04	Dark Spots without A Trace – A Case of Melanoma of Unknown Primary in the Liver
101481	Harshita	Dubey	India	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 04	Patterns of Liver Metastasis in Ovarian Cancer
200198	Akiko	Saito	Japan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 04	Reconsidering Cholangiolocellular Carcinoma from Two Cases Presenting with Different Characteristics
200226	Masood	Karim	Pakistan	Oral	March	29	Friday	AM	Metastatic Liver Tumors, CCC & Others 04	Eus Role in Defining Endoscopic and Histopathological Spectrum of Liver Lesions -South Asian Study
100075	Maurice	Michel	Germany	Oral	March	29	Friday	AM	Other Infection in Liver Disease 01	Lower Incidence of Adverse Liver Outcomes and HCC in Patients with Chronic Liver Disease and HIV
100085	Jian	Wu	China	Oral	March	29	Friday	AM	Other Infection in Liver Disease 01	Genotype 4 Hev Infection Trigger the initiation and Development of Acute Pancreatitis
100438	Ruochan	Chen	China	Oral	March	29	Friday	AM	Other Infection in Liver Disease 01	A Nomogram for Diagnosing Infection in Older Patients with Acold: A Nationwide Prospective Study
100538	Qian	Zhu	China	Oral	March	29	Friday	AM	Other Infection in Liver Disease 01	Imprinted Sars-Cov-2 Humoral Immunity induces A High Omicron Reinfection Risk in Cirrhotic Patients
100842	Jaqueline S.	Arsenal	Philippines	Oral	March	29	Friday	AM	Other Infection in Liver Disease 01	Clinical Profile and Outcome of Patients with Hepatic Tuberculosis
100995	Rian Ka	Praja	Indonesia	Oral	March	29	Friday	AM	Other Infection in Liver Disease 02	Molecular Mechanisms of Epigallocatechin Gallate to Treat Granulomatous Hepatitis Caused by Q Fever
101075	Reina	Sasaki-Tanaka	Japan	Oral	March	29	Friday	AM	Other Infection in Liver Disease 02	In Vitro and in Vivo Hepatitis A Virus Infection Models for Anti-Hav Drugs Screening
101172	Tianxu	Liu	China	Oral	March	29	Friday	AM	Other Infection in Liver Disease 02	An Immunocompetent Mongolian Gerbil Model for Hepatitis E Virus Genotype 1 Infection
101424	Sunil	Taneja	India	Oral	March	29	Friday	AM	Other Infection in Liver Disease 02	Plasma Exchange As A Rescue Therapy for Severe Prolonged Cholestasis in Acute Viral Hepatitis
101456	Moinak	Sen Sarma	India	Oral	March	29	Friday	AM	Other Infection in Liver Disease 03	Small Intestinal Bacterial Overgrowth in Liver Disease: Do Jejunal Cultures Predict Outcome?
101718	Yu-Chen	Fan	China	Oral	March	29	Friday	AM	Other Infection in Liver Disease 03	Global, Regional, and National Burdens of Hev from 1990 to 2019 and forecasted Incidence in 2030
101780	Necati	Ormeci	Turkey	Oral	March	29	Friday	AM	Other Infection in Liver Disease 03	Percutaneous Treatment of Hydatid Cysts with the Ormeci Technique
200112	Tianxu	Liu	China	Oral	March	29	Friday	AM	Other Infection in Liver Disease 03	Hepatitis E Virus infects Human Testicular Tissue and Sertoli Cells
100458	Laurence	Laurel	Philippines	Oral	March	29	Friday	AM	Other Infection in Liver Disease 04	Hepatic Tuberculosis Masquerading As Hepatocellular Carcinoma : A Case Report
101453	Srijaya	Sreesh	India	Oral	March	29	Friday	AM	Other Infection in Liver Disease 04	We Did not Look for It Because It was Everywhere : the Ubiquitous Presence Unveiled
200209	Rui	Zhang	China	Oral	March	29	Friday	AM	Other Infection in Liver Disease 04	Gas Sonogram within Ablation Zone: A Strong indicator of Post-Ablation Infection in Liver Malignancy
200256	Hsin-Yi	Chen	Taiwan	Oral	March	29	Friday	AM	Other Infection in Liver Disease 04	Hepatobiliary Tuberculosis Mimicking Hepatic Malignancy
101342	Hyun-Cheol	Kang	South Korea	Oral	March	29	Friday	PM	RadioTherapy 01	Contrast-Enhanced Volume of the Hepatocellular Carcinoma Treated with Carbon-Ion Radiation Therapy
101729	Taito	Fukushima	Japan	Oral	March	29	Friday	PM	RadioTherapy 01	Comparison of Carbon Ion RadioTherapy and Transarterial Chemoembolization for HCC Larger Than 3 Cm
101947	Prabhjyoti	Pahwa	India	Oral	March	29	Friday	PM	RadioTherapy 02	Prognostic Role of Serum Vegf and Hgf Post Sbrt in Advanced Hepatocellular Carcinoma
101037	Kojima	Masayuki	Japan	Oral	March	29	Friday	PM	Robotic Surgery 01	Standardization of Robot-Assisted Right Side Hepatectomy in Our Hospital
101168	Yukio	tokumitsu	Japan	Oral	March	29	Friday	PM	Robotic Surgery 01	Surgical Techniques of Liver Parenchymal Transection in Robot-Assisted Liver Resection
101960	Kazuhiro	Matsuda	Japan	Oral	March	29	Friday	PM	Robotic Surgery 01	Robot-Assisted Liver Resection Guided by Icg Fluorescence Imaging and Artificial Intelligence
102037	Taiga	Wakabayashi	Japan	Oral	March	29	Friday	PM	Robotic Surgery 01	Robot-Assisted Limited Anatomic Liver Resection: A Report on the Current Status
200033	Yutaro	Kato	Japan	Oral	March	29	Friday	PM	Robotic Surgery 02	Robotic Surgery Will Be the Standard Approach to Highly Complex Minimally Invasive Liver Resection
200233	Hideaki	Iwama	Japan	Oral	March	29	Friday	PM	Robotic Surgery 02	Long-Term Outcomes of Robotic Surgery for initial Liver Resection of Colorectal Liver Metastases
200284	Yoichi	Kawano	Japan	Oral	March	29	Friday	PM	Robotic Surgery 02	Inventions of Robot-Assisted Laparoscopic Liver Resection in Our Department
100208	Suprabhat	Giri	India	Oral	March	29	Friday	PM	Surgery & Transplantation 01	Risk of Vascular Complications with Living & Deceased Donor Liver Transplantation – A Meta-Analysis
100404	Ze	Xiang	China	Oral	March	29	Friday	PM	Surgery & Transplantation 01	Impact of Preoperative Infection on the Outcomes of Liver Transplant Recipients
100457	Shengjun	Xu	China	Oral	March	29	Friday	PM	Surgery & Transplantation 01	Bmscs Ros-Responsively Secreting Hepatocyte Growth Factor for attenuating Hepatic Iri
100661	Yongquan	Chi	China	Oral	March	29	Friday	PM	Surgery & Transplantation 01	Novel System for Organ Preservation: Feed Macrophages with Ceria Nanoparticles
100811	Channa	Jayasekera	United States	Oral	March	29	Friday	PM	Surgery & Transplantation 01	Long-Term Outcomes of Fenofibrate for Treatment of Liver Allograft ischemic Cholangiopathy
100962	Liangshuo	Hu	China	Oral	March	29	Friday	PM	Surgery & Transplantation 01	Utilization of Elderly Donors in Liver Transplantation for Patients with Hepatocellular Carcinoma
101225	Dai Hoon	Han	South Korea	Oral	March	29	Friday	PM	Surgery & Transplantation 02	The Impact of Age on Liver Regeneration after Living Donor Right Hemihepatectomy in Elderly Donor
101665	Ruiqi	Sun	China	Oral	March	29	Friday	PM	Surgery & Transplantation 02	The therapeutic Potential of Self-Assembled Rapamycin Nanoparticles in Allograft Rejection
101840	tomokazu	KUSANO	Japan	Oral	March	29	Friday	PM	Surgery & Transplantation 02	Laparoscopic Anatomical Liver Resection with Icg Real-Time Navigation
101932	Jan Axel Lopez	Yusi	Philippines	Oral	March	29	Friday	PM	Surgery & Transplantation 02	Alpps Vs Conventional Techniques in Hepatitis Related HCC: A Systematic Review and Meta Analysis
102022	Saurabh	Singhal	India	Oral	March	29	Friday	PM	Surgery & Transplantation 02	Central Hepatectomy with Vascular Reconstruction (Video Abstract)
200026	Koichi	Nakanishi	Japan	Oral	March	29	Friday	PM	Surgery & Transplantation 02	Risk Factors for Surgical Site Infection after Hepatectomy in Our Facility
100160	Jai Young	Cho	South Korea	Oral	March	29	Friday	PM	Surgery & Transplantation 03	Comparative Study of Laparoscopic Left Lateral Liver Resection Vs Ablation for Single Small HCC
100254	Şencan	Acar	Turkey	Oral	March	29	Friday	PM	Surgery & Transplantation 03	Is It Possible to Minimize Liver I/R Damage and increase Regeneration Capacity?
101310	Muhsin Murat Muhiş	Harputluoglu	Turkey	Oral	March	29	Friday	PM	Surgery & Transplantation 03	Outcomes of Patients with Primary Sclerosing Cholangitis after Liver Transplantation
101506	Citra	Aryanti	Indonesia	Oral	March	29	Friday	PM	Surgery & Transplantation 03	Alternative Hepatic Artery Conduit in Liver Transplantation: A Bayesian Network-Meta Analysis.
101757	Vienne	Pinlac	Philippines	Oral	March	29	Friday	PM	Surgery & Transplantation 03	Hepatic Artery Pseudoaneurysm with Arterio-Biliary Fistula Following Liver Transplantation
101897	Pranav	Vatsayan	India	Oral	March	29	Friday</			

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
101110	Akihiro	Seki	Japan	Oral	March	29	Friday	PM	Surgery & Transplantation 04	The Evaluation for Causes and Status of Fatty Liver after Liver Transplantation.
101903	Akira	Koizumi	Japan	Oral	March	29	Friday	PM	Surgery & Transplantation 04	A Comparative Study of Laparoscopic Liver Resection for the Segment 4 Superior and inferior Area
102043	Junhao	Zheng	China	Oral	March	29	Friday	PM	Surgery & Transplantation 04	A Multi-Center Nomogram to Predict the Difficulty of Minimally Invasive Liver Resection for HCC
102074	Liangshuo	Hu	China	Oral	March	29	Friday	PM	Surgery & Transplantation 04	Effect of Ursodeoxycholic Acid on Sars-Cov-2 Infection in Patients with Liver Transplantation
200011	Masaki	Ueno	Japan	Oral	March	29	Friday	PM	Surgery & Transplantation 04	Laparoscopy Specific Dorsal Approach to the Middle Hepatic Vein in Performing Left Hemihepatectomy
200018	Hiroji	Shinkawa	Japan	Oral	March	29	Friday	PM	Surgery & Transplantation 04	Laparoscopic and Open Minor Hepatectomy for Patients with Clinically Significant Portal Hypertension
101194	Masanori	Inoue	Japan	Oral	March	29	Friday	AM	Systemic ChemoTherapy & Oncology 01	Optimal Radiological Assessment for HCC with Macrovascular Invasion During Systemic Therapy
101914	Shuntaro	Obi	Japan	Oral	March	29	Friday	AM	Systemic ChemoTherapy & Oncology 01	atz + Bev for Advanced HCC: If Liver Function and Ps Can Be Maintained, Post-Treatment is Possible
100441	Alexis Danica B.	Drilon	Philippines	Oral	March	29	Friday	AM	Systemic ChemoTherapy & Oncology 02	Iraes: Immune Mediated Thrombocytopenia after Durvalumab Infusion for Hepatocellular Carcinoma
100729	Kaori	Mukai	Japan	Oral	March	29	Friday	AM	Systemic ChemoTherapy & Oncology 02	Comparative Efficacy of Regorafenib, Cabozantinib, and Ramucirumab for Unresectable HCC
101258	Chihiro	Miwa	Japan	Oral	March	29	Friday	AM	Systemic ChemoTherapy & Oncology 02	Safety and Efficacy of Durvalumab Monotherapy for Unresectable HCC in the Real-World Practice
101270	Hiroaki	Abe	Japan	Oral	March	29	Friday	AM	Systemic ChemoTherapy & Oncology 02	Multicenter Observational Study to Evaluate Clinical Outcomes of Abc Conversion Therapy
101858	Yongwei	Hu	China	Oral	March	29	Friday	AM	Systemic ChemoTherapy & Oncology 02	Metalloimmunology-Based Nanoclusters Activate the Immune to Enhance Pembrolizumab Plus Lenvatinib
102040	Akihiro	Fujisawa	Japan	Oral	March	29	Friday	AM	Systemic ChemoTherapy & Oncology 02	Association Between Tumor Morphology and Efficacy of atezolizumab Plus Bevacizumab for Advanced HCC
100061	Edwin	Njoto	Indonesia	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 01	Systemic Plus Hepatic Arterial Infusion ChemoTherapy in Unresectable Intrahepatic Cholangiocarcinoma
100748	Shuya	Maeshima	Japan	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 01	Comparison of Therapeutic Effects of Lenvatinib and Haic for Unresectable HCC with Vascular Invasion
100793	Takeshi	Matsumoto	Japan	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 01	Validity of the 7-11 Criteria in Transarterial Chemoembolization for Intermediate Stage
102063	Shiro	Miyayama	Japan	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 01	Efficacy of Tace Guidance Software for Hepatocellular Carcinoma in the Caudate Lobe
200141	Yahua	Li	China	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 01	Tace Combined with Donafenib Plus Pd-1 for Unresectable HCC : A Retrospective Study
100417	Jessica T.	Wen	United States	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 02	Afp Response Patterns after Radioembolization of Hepatocellular Carcinoma Predicts Disease Outcomes
100785	Duy Anh	Nguyen	Vietnam	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 02	Early Response to Haic Using Lipiodol, Cisplatin, and 5-Fu for Locally Advanced HCC in Vietnam
101325	Burak	Demir	Turkey	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 02	Radioembolization with 90Y Resin Microspheres and Voxel-Based Dosimetry with Integrated 90Y Pet/Mri
101528	Haruyuki	Takaki	Japan	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 02	Hepatic Artery Embolization Promotes T-Cell Exhaustion in Rat Hepatocellular Carcinoma Model.
101584	Hiroto	Ota	Japan	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 02	Efficacy of Haic New-Fp for Unresectable Advanced Intrahepatic Cholangiocarcinoma
101875	Shuntaro	Obi	Japan	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 03	Hepatic Arterial Infusion ChemoTherapy Survives As A Last Resort
101928	Zijian	Zhang	China	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 03	Secretome Methods Show An Active Arachidonic Acid Metabolism indicates Tace Response in HCC Patients
200042	Dan	Zhao	China	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 03	Transcatheter Arterial Embolization of Hepatic Hemangiomas: Efficacy and Predictors of Response
200054	Zhongzhi	Jia	China	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 03	In-Stent Restenosis after Stenting for Superior Mesenteric Artery Dissection
200055	Zhongzhi	Jia	China	Oral	March	29	Friday	PM	TACE, HAIC & Vascular interventions 03	A Change in Strategy for Filter Choice Leads to Improved Filter Retrieval Rates
100096	Naoki	Hashimoto	Japan	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 01	The Relationship Between Pancreatic Hormone and Liver in Acute Hepatic Failure.
100242	Zhihui	Li	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 01	Thymosin α 1 Improves Immune Imbalance in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
100354	Jia	Chen	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 01	Baicalin Alleviates Acfl by Promoting Trem2-Dependent M2 Macrophage Polarization and Efferocytosis
100364	Jing	Liang	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 01	Prospective Study of the Effect of Tpo on Platelets and Prognosis in Patients with Acfl
100374	Yejiqiong	Zhang	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 01	Long-Term Efficacy and Safety of Three Potent Nas in the Treatment of HBV-Acfl: 144-Week Data
100378	Yu Shan	Liu	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 02	Mnps Improves the Efficiency of Infection Diagnosis and Treatment in Acute-on-Chronic Liver Failure
100399	Arjun	Maria	India	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 02	Crrt in Children with Hepatitis A Virus Associated Acute Liver Failure with Advanced Encephalopathy
100476	Sunil	Taneja	India	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 02	Outpatient intensive Nutrition Therapy Improves Survival and Frailty in Acfl: Randomized Trial
100525	Rui	Song	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 02	Alta: A Simple Nutritional Prognostic Score for Patients with HBV-Acfl
100576	Vivek	Saini	India	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 02	forecasting initial 15-Day Mortality in Alcohol Related Acute on Chronic Liver Failure (Acfl)
100656	Jianhua	Rao	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 03	Xbpl Mediating Nf κ B Promotes Macrophage Derived Inflammation Via Mt2 Transcript in Liver Iri
100697	Pratibha	Garg	India	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 03	Biomarker Discovery, Validation & Pathways in Infection Related Acute-on-Chronic Liver Failure
100743	Yamin	Wang	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 03	Predictive Model Based on Pni for Infection in Acute-on-Chronic Liver Failure
100799	Guan-Huei	Lee	Singapore	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 03	Hepatitis E Virus Infection Portends High Mortality in Patients with Acute-on-Chronic Liver Failure
100843	Xiaoli	Zhang	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 03	Xp1 Mediating Nf κ B Promotes Liver Regeneration and Attenuating Hepatocytes Apoptosis
100848	Shan	Fu	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 04	Activating Cholinergic Pathway Attenuates Liver Injury by Inhibiting Mkl1-Mediated Necroptosis
100929	Xiao	Zhong	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 04	Niclodamide Inhibits Macrophage Ferroptosis Against Lps/D-Galn-Induced Acute Liver Failure
101039	Jan Axel	Yusi	Philippines	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 04	Comparison of 28 Day Survival of Patients with Alf and Acfl Treated with Dpmas
101122	Jing	Liang	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 04	Tpo Promotes Hepatocyte Regeneration by Elevating Platelets in Rats with Acute Liver Failure
101255	Yali	Feng	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 04	Exosomes from Senescent Hepatocytes Activate Hscs and Protect Against Acute Liver Failure by Itga5
101397	Beiling	Li	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 05	Dpmas Therapy in Patients with Liver Failure: A Non-Randomized Cluster-Controlled Study (Padstone)
101409	Qin	Ning	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 05	Clinical Characteristics and Risk Factors of End-Stage Liver Disease Complicated by Infections
101425	Hanisha	Hemmani	Pakistan	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 05	Fulminant Hepatic Failure in Pregnancy Challenges, Etiology, Management and Its Associated Mortality
101524	Qi	Huang	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 05	Role of Plasma-Derived Exosomal Lncrna in Regulating the Systemic Inflammatory Response in HBV-Acfl
101538	Zhen	Tian	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 05	Lps Promotes Inflammation Via Proteasomal Degradation of atg13 in Hscs During Acfl
101574	Qing	Ye	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 06	The Role of L3-Pmi in the Prognostic Evaluation of Patients with Acute-on-Chronic Liver Failure
101620	Jihyun	Sung	Japan	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 06	Activation of Hepatocyte P53 Triggers Acute Liver Failure with Multiple Organ Injury.
101635	Jun	Li	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 06	Evaluating the Life-Saving Potential of Liver Transplants for Acfl with Circulatory Failure
101647	Jun	Li	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 06	Longitudinal Single-Cell Profiling Unveils Distinct Immune Traits Linked to Acfl Progression
101687	Xue-Fei	Wei	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 06	Hypomethylation of T11A Predicts the Prognosis of Achblf
101691	Xing	Su	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 07	Hypermethylation of Glutathione Peroxidase 4 Promoter Predicts Poor Prognosis of HBV-Acfl
101727	Yu-Chen	Fan	China	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 07	Single-Cell Landscape of Immunological Responses in Acute-on-Chronic Hepatitis B Liver Failure
101835	Cosmas Rinaldi Adithya	Lesmana	Indonesia	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 07	Esophageal Varices Stratification As Early Sign of Portal Hypertension in Acfl: Apasl-Aarc Study
101918	Mahathi	Avadhanam	India	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 07	Rifaximin Has No Beneficial Role in Acfl Patients Admitted to Icu - A Double Blind Rct
101948	Sushmita	Pandey	India	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 07	Plasma Multi-Omics Reveals Gut Dysregulated Metaproteome and Metabolites As Poor Outcomes in Alf
101976	Ashish	Kumar	India	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 08	Plasma Exchange Improves 30-Day But not 90-Day Survival of Alcohol-Related Acfl: A Meta-Analysis
102006	Anand	Kulkarni	India	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 08	Patients with Decompensated Cirrhosis Have Poorer Physical Functioning Than Patients with Acfl
102007	Rakhi	Maiwall	India	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 08	High Serum Bile Acids Drive Aki Progression and Terlipressin Non-Response in Patients with Acfl
102031	Ashok	Choudhury	India	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 08	Second Hit Acute insult increases Mortality in Patients of Acute-on-Chronic Liver Failure
200144	Natsuko	Inagaki	Japan	Oral	March	30	Saturday	AM	Acute Liver Failure & ACLF 08	Lpca3/Lpld12 Deficiency in the Liver Ameliorates Acetaminophen-Induced Acute Liver Injury
100086	Jian	Wu	China	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 09	Noninvasive Proteomic Biomarkers for Hev-Related Acute Liver Failure
100469	Xiaoze	Wang	China	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 09	Outcomes and Risk Factors of Early Liver Injury after Transjugular Intrahepatic Portosystemic Shunt
100495	Jing	Liang	China	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 09	Prospective Study of the Effect of Tpo on Platelets and Prognosis in Patients with Acfl
100573	Thanh Huu	Nguyen	Vietnam	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 09	A Case Report of Hepatic Amyloidosis Presenting As Acute-on-Chronic Liver Failure
100723	Naohiro	Wada	Japan	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 09	Investigating Factors Involved in the Rate of the Examination Success of Transjugular Liver Biopsy.
100847	Juan	Li	China	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 09	Association of Coexistent Hbsag and Anti-Hbs with Prognosis of HBV-Acfl Patients
100969	Qiao	Zhang	China	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 09	Long-Term Prognosis of HBV-Acfl Patients with Extremely Low-Level Viremia
101021	Ashish	Kumar	India	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 09	Diabetes Mellitus Linked to Higher Mortality in Alcohol-Related Acute-on-Chronic Liver Failure
101154	Jose orlando	Nicolas	Philippines	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 10	Experience on Use of Dpmas Among Patients with Acfl and Decompensated Liver Cirrhosis - Case Series
101280	Vinod	Arora	India	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 10	Antibiotics and Steroids for 4-Weeks in Acfl-Ah with Steroid Response Showed Reduction of Infections
101331	Moinak	Sen Sarma	India	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 10	Ascites in Hepatitis A-Induced Liver Failure: Does It Impact Outcome?
101442	Masazumi	onuki	Japan	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 10	Recent Trend of Acute Hepatitis and Acute Liver Failure in Our Hospital
101483	Tianzhi	Ni	China	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 10	Isoproterenol Attenuates Lps/D-Galn-Induced Liver Injury Through β 2-Arrestin2 Exerts Anti-inflammatory
101509	Jia	Chen	China	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 10	Cost-Effectiveness Analysis of Two Non-Biological Artificial Liver Modes in Early HBV-Acfl
101550	Zhen	Tian	China	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 10	Prognostic Value of Plasma Level of Superoxide Dismutase in HBV-Related Acfl
200005	Nazish	Butt	Pakistan	Oral	March	30	Saturday	PM	Acute Liver Failure & ACLF 10	Fulminant Hepatic Failure Etiology, Manifestation and Outcomes: Experience of Tertiary Care Hospital.
100747	Xiaonan	Xiang	China	Oral	March	30	Saturday	AM	Biliary Disease 01	Expression Pattern and Clinical Significance of Myeloid Checkpoint Vista in Cholangiocarcinoma
101048	Nurarifah	Ali	Indonesia	Oral	March	30	Saturday	AM	Biliary Disease 01	Reducing Gamma Glutamyl Transferase after Steroid Administration in Biliary Atresia
101066	Syania	Octariyandra	Indonesia	Oral	March	30	Saturday	AM	Biliary Disease 01	Methylprednisolone Reduces Mmp-7 As A Marker of Fibrosis Progression in Biliary Atresia
101143	Farahdina	Farahdina	Indonesia	Oral	March	30	Saturday	AM	Biliary Disease 01	Rct Study in Biliary Atresia: Effect of Methylprednisolone on Liver Function Tests
101175	Hiroki	Inada	Japan	Oral	March	30	Saturday	AM	Biliary Disease 02	Clinical Utility of Comprehensive Genomic Profiling Tests for Advanced Biliary Tract Cancer
200004	Asgar	Ali	India	Oral	March	30	Saturday	AM	Biliary Disease 02	Diagnostic and Prognostic Significance of the Pten Gene in Periampullary Cholangia.
200105	Sachiko	Kanai	Japan	Oral	March	30	Saturday	AM	Biliary Disease 02	Tnfrsf14 and Light Are Upregulated in Biliary Epithelia of Primary Sclerosing Cholangitis
200223	Lixia	Xu	China	Oral	March	30	Saturday	AM	Biliary Disease 02	Gemcitabine and Cisplatin Plus Pd-L1 Inhibitors with Lenvatinib in Advanced Biliary Tract Cancer
100144	Zhipeng	Sun	China	Oral	March	30	Saturday	AM	Biliary Disease 03	Haic, Lenvatinib, and Pd-1 Inhibitors Versus Gc ChemoTherapy for Advanced Biliary Tract Cancer
100400	Arjun	Maria	India	Oral	March	30	Saturday	AM	Biliary Disease 03	Cholelithiasis in Children- Clinical Spectrum
100776	Mohammad	Azam	Bangladesh	Oral	March	30	Saturday	AM	Biliary Disease 03	Ca19-9, Ca19-9/Crp and Ca19-9/Bilirubin in Differentiating Benign and Malignant Obstructive Jaundice
100885	Alankrita	Madhur	India	Oral	March	30	Saturday	AM	Biliary Disease 03	Etiological Spectrum of Paucity of Intrahepatic Bile Duct (Pihbd) in Infants
1010										

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
100331	Sae	Yumita	Japan	Oral	March	30	Saturday	AM	Case Report 01	Cytokine Release Syndrome Caused by the Durvalumab Plus Tremelimumab Combination Therapy for HCC
100370	Po-Heng	Chuang	Taiwan	Oral	March	30	Saturday	AM	Case Report 01	Gastric Bleeding in Sorafenib for HCC Drop Metastases
100455	Ma. Regina D.	Dimaculangan	Philippines	Oral	March	30	Saturday	AM	Case Report 01	Recovery of Severe Acute Hepatic Graft-Versus-Host Disease in A Recently Transplanted Pre-B Cell All
100456	Laurence	Laurel	Philippines	Oral	March	30	Saturday	AM	Case Report 02	Unmasking Hepatoid Adenocarcinoma of the Stomach Mimicking As Hepatocellular Carcinoma: A Case Report
100539	Chihei	Sugihara	Japan	Oral	March	30	Saturday	AM	Case Report 02	A Case of Neuroendocrine Carcinoma Caused Obstructive Jaundice by Extensive Hepatic Infiltration
100541	Chihei	Sugihara	Japan	Oral	March	30	Saturday	AM	Case Report 02	A Case of Cholangitis As Immune-Related Adverse Events with Biliary Infection after Cholangiography
100589	Michiko	Koga	Japan	Oral	March	30	Saturday	AM	Case Report 02	Corticosteroid Therapy for Prolonged Jaundice and Pruritus in HIV Patients with Acute Hepatitis A
100611	Michiko	Koga	Japan	Oral	March	30	Saturday	AM	Case Report 02	Detection of Etv-Associated Drug Resistance Mutation S202G in A Case of HBV/HIV Coinfection
100621	Haily	Vora	United States	Oral	March	30	Saturday	AM	Case Report 02	A Rare Case of Advanced Hepatocellular Carcinoma in Acute Intermittent Porphyria without Cirrhosis
100651	Enrico J. A.	Marpaung	Indonesia	Oral	March	30	Saturday	AM	Case Report 02	Peritonitis Tuberculosis - A Diagnostic Challenge: Case Report
100658	Enrico J. A.	Marpaung	Indonesia	Oral	March	30	Saturday	AM	Case Report 03	A Rare Case of Hirschsprung's Disease in An Adult Patient: Case Report
100715	Jose Maria I.	Gonzalez	Philippines	Oral	March	30	Saturday	AM	Case Report 03	A Case of HCC with Inferior Vena Cava and Right Atrium Tumor Thrombus in A Patient with Covid-19
100769	Jose Maria I.	Gonzalez	Philippines	Oral	March	30	Saturday	AM	Case Report 03	A Case of Hemobilia Secondary to Polyarteritis Nodosa with Underlying Gallbladder Hemangioma
100790	Giang	Nguyen	Vietnam	Oral	March	30	Saturday	AM	Case Report 03	Combine Hepatectomy and Flow Modulation Surgery for Patient with HCC and Gastroesophageal Varices
100815	European Henley	Sanchez	Philippines	Oral	March	30	Saturday	AM	Case Report 03	Patients with Hepatosplenic Schistosomiasis Who Underwent Modified Sugiura Procedure: A Case Series
100851	Salahuddin	andam	Philippines	Oral	March	30	Saturday	AM	Case Report 03	atypical Nutcracker'S Syndrome in Polycystic Liver Disease: A Case Report
100861	Nida	Ali	Pakistan	Oral	March	30	Saturday	AM	Case Report 03	Mother to Child Transmission of HBV - Role of Birth-Dose and Hbg for Prevention
100896	Dinu Abirami	Prem Kumar	India	Oral	March	30	Saturday	AM	Case Report 04	Successful Downstaging of Hepatocellular Carcinoma with Immunotherapy
100924	Erika Johanna	Tañada	Philippines	Oral	March	30	Saturday	AM	Case Report 04	Malignant Hepatic Solitary Fibrous Tumor in A 28- Year Old Filipino Male : A Case Report
101090	Deepa	Janakiraman	India	Oral	March	30	Saturday	AM	Case Report 04	An Unusual Synergy with Depleting Energy
101218	Lanxia	Zhang	China	Oral	March	30	Saturday	AM	Case Report 04	Ebv+ Lymphoepithelioma-Like Cholangiocarcinoma in A Woman with HBV Treated by Mwa: A Case Report
101235	Areangela	Angeles	Philippines	Oral	March	30	Saturday	AM	Case Report 04	A Case Report of Giant Cavernous Hepatic Hemangioma with Kasabach-Merritt Syndrome
101259	Takayoshi	Oikawa	Japan	Oral	March	30	Saturday	AM	Case Report 04	A Case of HCC with A Remarkable Response Following of Durvalumab/Tremelimumab after Systemic Therapy
101285	Yukie	Nakadai	Japan	Oral	March	30	Saturday	AM	Case Report 04	A Case of Hepatocellular Carcinoma 37 Years after Surgery for Truncus Arteriosus
101315	He	Wang	China	Oral	March	30	Saturday	PM	Case Report 05	Recurrence of Myopathy after Liver Transplantation for Patients with End-Stage Gsd Type Iiia
101468	Dr. Md. Kamal	Parvej	Bangladesh	Oral	March	30	Saturday	PM	Case Report 05	A Thirteen-Years-Old Child with Acute Pancreatitis and Stemi Mimics - A Diagnostic Dilemma
101539	Shuhei	Arima	Japan	Oral	March	30	Saturday	PM	Case Report 05	Long-Term Follow Up of Patient with Occurrence of Autoimmune Hepatitis Post-Covid-19 Vaccination
101549	Yuma	inoue	Japan	Oral	March	30	Saturday	PM	Case Report 05	Walled-off Necrosis after total Aortic Arch Replacement Treated Successfully by Eus-Guided Drainage
101566	Keishi	Ouchi	Japan	Oral	March	30	Saturday	PM	Case Report 05	Acute Liver Injury and Bilateral Pulmonary Artery Thrombosis Due to Hypereosinophilic Syndrome
101892	Lutfi	Zunardi	Indonesia	Oral	March	30	Saturday	PM	Case Report 05	How to Manage HCC Patients with High-Risk Pe and High-Risk Bleeding: Can We Perform Thrombolysis?
101934	Hiroshi	Mitsui	Japan	Oral	March	30	Saturday	PM	Case Report 06	A Case of Type 1 Diabetes Complicated with Nonalcoholic Steatohepatitis and Glycogenic Hepatopathy
101996	Vivien	Ang	Philippines	Oral	March	30	Saturday	PM	Case Report 06	Fibrolamellar Hepatocellular Carcinoma Treated with Alpps: A Case Report
102069	Taisei	Iwasa	Japan	Oral	March	30	Saturday	PM	Case Report 06	A20 Haploinsufficiency Complicated by Autoimmune Hepatitis
200086	Ronell	Lee	Philippines	Oral	March	30	Saturday	PM	Case Report 06	Hematemesis Unveiling Gastric Tuberculosis: Emphasizing Diagnostic Value of Endoscopic Ultrasound
200113	Ronell	Lee	Philippines	Oral	March	30	Saturday	PM	Case Report 06	Eosinophilic Duodenitis with Concomitant Eosinophilic Esophagitis
200126	Nadira	Sanjaya	Indonesia	Oral	March	30	Saturday	PM	Case Report 06	Salmonella Infection Manifesting As Typhoid Hepatitis: An Uncommon Presentation of Common Disease
200221	Mithra	Prasad	India	Oral	March	30	Saturday	PM	Endoscopic Treatment 01	A Novel Hemostatic Spray to Tackle Post-Evbl and Post-Glue Ulcer Bleed Patients
200267	Daishi	Kabemura	Japan	Oral	March	30	Saturday	PM	Endoscopic Treatment 01	Risk Factor of Severe Adverse Events with Eus-Hgs
100306	Priya	Nair	India	Oral	March	30	Saturday	PM	Endoscopic Treatment 02	Drug Eluting Nanoyarn Integrated Biliary Metallic Stents to Prevent Stent Occlusion
101035	Mayur	Satai	India	Oral	March	30	Saturday	PM	Endoscopic Treatment 02	Sucralfate Vs Proton Pump Inhibitor(Ppi) Vs Combination Post Esophageal Variceal Band Ligation
101131	Nimrah	Mehak	Pakistan	Oral	March	30	Saturday	PM	Endoscopic Treatment 02	Outcome of Upper Gastrointestinal Bleeding Secondary to Pud : Experience from Karachi, Pakistan
101326	Hendra	Koncoro	Indonesia	Oral	March	30	Saturday	PM	Endoscopic Treatment 02	A Large Stone in Neglected Cbd Stent Treated with Single-Operator Cholangioscopy Guided Lithotripsy
101457	Hafiz Mughees	ather	Pakistan	Oral	March	30	Saturday	PM	Endoscopic Treatment 02	Comparison of Severity of Pancreatitis with and without Diclofenac Sodium in Post Ercp Patients
101485	Murat	Kekilli	Turkey	Oral	March	30	Saturday	PM	Endoscopic Treatment 03	Pre-cut Papillotomy Vs. Standard Sphincterotomy Regarding the Duration of Hospitalization
101909	Yan	He	China	Oral	March	30	Saturday	PM	Endoscopic Treatment 03	Thromboelastography and the Risk of Major Bleeding after Endoscopic Variceal Treatment in Cirrhosis
200238	Yuri	Starkov	Russia	Oral	March	30	Saturday	PM	Endoscopic Treatment 03	Experience with Intraductal Rfa for Neoplasms of the Major Duodenal Papilla with Intraductal Spread.
200239	Ayubkhan	Vagapov	Russia	Oral	March	30	Saturday	PM	Endoscopic Treatment 03	Results of Endoscopic Operations for Adenomas of the Major Duodenal Papilla
200240	Ayubkhan	Vagapov	Russia	Oral	March	30	Saturday	PM	Endoscopic Treatment 03	Endoscopic Classification of Neoplasms of the Major Duodenal Papilla.
100451	Yi Rou	Bah	Singapore	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 01	Gut-Bone-Liver Axis: Interplay of Gut Microbiome and Myeloid Cells in MASLD
100636	Hong-Hsing	Liu	Taiwan	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 01	Compensatory Metabolic Regulation of Gut Microbiome by Host Immunity
100685	Yinji	Liang	China	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 01	Gut Microbiota and Metabolites Dysbiosis of NASH-HCC and Related Neuropsychiatric Disorders in Mice
100750	Karlynn	Goh	Singapore	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 01	Targeted Dietary Modulation of Gut Microbiome in An Animal Model of MASLD
100844	Damien	Chua	Singapore	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 01	Dietary Impact on Gut Permeability in MASLD
101207	Ruqi	Tang	China	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 02	Multi-Omics Reveal Microbial Determinant Impacting Treatment Response in Primary Biliary Cholangitis
101343	Nazeha A.	Khalil	Egypt	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 02	Knowledge and Awareness of Probiotics Dietary Sources Assessments: Gut-Liver Axis in Focus
101405	Moinak	Sen Sarma	India	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 02	Intestinal Permeability in Cirrhosis: Correlation of Biomarkers and Urine Polyethylene Glycol
101753	Yuki	Kidoguchi	Japan	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 02	The Novel Findings in Liver ischemia-Reperfusion Injury -Fasting and Short-Chain Fatty Acids-
101339	Jacob	Raja A S	India	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 03	The Association of H Pylori Infection with Minimal Hepatic Encephalopathy in Child A and B Cirrhosis
101602	Yen-Hsuan	Ni	Taiwan	Oral	March	30	Saturday	AM	Gut Liver Axis and Microbiome 03	Antagonism of Gut R. Gnavus and A. Muciniphila Modulates the Clinical Course of Chronic Hepatitis B
100091	Takao	Miwa	Japan	Oral	March	30	Saturday	AM	Liver Cirrhosis 01	Dysphagia Impairs Health-Related Quality of Life in Patients with Chronic Liver Disease
100105	Xiaoxin	Wu	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 01	Mapping Trends and Hotspots in Clinical Research on Bacterial Infections in Cirrhosis
100159	Khien	Yu	Vietnam	Oral	March	30	Saturday	AM	Liver Cirrhosis 01	Treatment of Gi Bleeding Due to Portal Hypertension in Vietnam
100174	Rui	Huang	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 01	Predictors of Liver-Related Readmissions in Cirrhotic Patients: A Retrospective Study
100266	Kessarín	Thanapirom	Thailand	Oral	March	30	Saturday	AM	Liver Cirrhosis 01	Outcomes During Hospitalization in Cirrhotic Patients with Multidrug-Resistant Bacterial Infection
100275	Grace	Wong	Hong Kong	Oral	March	30	Saturday	AM	Liver Cirrhosis 02	High Disease Burden of Significant Portal Hypertension in Diabetic Chronic Hepatitis B
100391	Akshay	Kale	India	Oral	March	30	Saturday	AM	Liver Cirrhosis 02	Comparison Between Predictors of Mortality in Patients of Chronic Liver Disease, Barring Aclf
100605	Chengbin	Zhu	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 02	A Rfh-Npt-Based Nomogram to Predict the Long-Term Survival of Liver Carcinoma : A Multicenter Study
100664	Seung Kang	Yoo	South Korea	Oral	March	30	Saturday	AM	Liver Cirrhosis 02	Comparison of Mortality Prediction of Meld, Meld-La, and Meld-3.0 on Korean Liver Cirrhosis Patients
100709	Jason	Chang	Singapore	Oral	March	30	Saturday	AM	Liver Cirrhosis 02	Diagnostic Accuracy of Micronas As Non-invasive Biomarkers for the Diagnosis of Liver Cirrhosis
100741	Jan Catherine	Carrera	Philippines	Oral	March	30	Saturday	AM	Liver Cirrhosis 03	Role of inflammatory Based Markers in the Diagnosis of Bacterial Infection Among Cirrhotic Patients
100753	Pooi Ling	Loi	Singapore	Oral	March	30	Saturday	AM	Liver Cirrhosis 03	Serum Ammonia Level Predicts Complications and Mortality in Clinically Stable Outpatient Cirrhotics
100798	Vishwa M	Dayal	India	Oral	March	30	Saturday	AM	Liver Cirrhosis 03	Serum Bnp Levels and 90 Day Mortality in Patients of Decompensated Liver Cirrhosis
100804	K. Rajender	Reddy	United States	Oral	March	30	Saturday	AM	Liver Cirrhosis 03	Efficacy of Continuous Terlipressin Infusion in Hrs-Aki in A Transplant-Enriched Population
100840	Che to Jimmy	Lai	Hong Kong	Oral	March	30	Saturday	AM	Liver Cirrhosis 03	Secular Trend of Disease Burden of Hydrothorax in Patients with Liver Cirrhosis
100879	Yichong	Jiang	Hong Kong	Oral	March	30	Saturday	AM	Liver Cirrhosis 04	Anticoagulants and Antiplatelet Agents Are Commonly Used in Patients with Cirrhosis
100891	Dinu Abirami	Prem Kumar	India	Oral	March	30	Saturday	AM	Liver Cirrhosis 04	Role of Spot Urine Sodium/Potassium Ratio in Predicting Acute Kidney Injury in Cirrhosis
100973	Chloe Ce	Lim	Singapore	Oral	March	30	Saturday	AM	Liver Cirrhosis 04	Change in Rotational Thromboelastometry Parameters in Patients with Cirrhosis after Transfusion
101123	Che to Jimmy	Lai	Hong Kong	Oral	March	30	Saturday	AM	Liver Cirrhosis 04	Mortality of Cirrhotic Patients with Hydrothorax Over the Last Two Decades
101253	Qin	Ning	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 04	Sting Activation Hampers HBV Replication But Promotes Liver Injury in Chb Concurrent with Nafld
101305	Naoya	Kanogawa	Japan	Oral	March	30	Saturday	AM	Liver Cirrhosis 05	Understanding the Current Status of Zinc Deficiency in Patients with Chronic Liver Disease
101321	Amarsanaa	Jazag	Mongolia	Oral	March	30	Saturday	AM	Liver Cirrhosis 05	Classification of 5,102 Mongolian Patients with Liver Cirrhosis by Causes
101323	Xu	Cao	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 05	The Rct Study of Jianpihuazhuoxingnao formula in Treatment of Cirrhosis Mild Hepatic Encephalopathy
101502	Jalal	Khan	Pakistan	Oral	March	30	Saturday	AM	Liver Cirrhosis 05	Friality Correlates with Greater Odds of Hepatic Encephalopathy,Ascites,&Sbp;A Study from Pakistan
101525	Chao	Sun	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 05	Predictive Performance Concerning Distinct Smi Cut-offs of Sarcopenia for Mortality Among Cirrhosis
101577	Ping	Zhu	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 05	Value of Thromboelastography in Prognosis Evaluation of Hospitalized Patients with Liver Cirrhosis
101711	Chan Jin	Yang	South Korea	Oral	March	30	Saturday	AM	Liver Cirrhosis 06	Prognostic Factor Which Can Predict Esophageal Varices Aggravation after Parto
101926	Yuki	Utakata	Japan	Oral	March	30	Saturday	AM	Liver Cirrhosis 06	Usefulness of Retinol-Binding Protein to Predict Mortality in Patients with Chronic Liver Disease
101969	Muhammad Bilal	Saifulhaq	Indonesia	Oral	March	30	Saturday	AM	Liver Cirrhosis 06	Interleukin-6 As Predictor of Hepatic Encephalopathy Incidence in Hepatic Cirrhosis Patients
102002	Akhil	Deshmukh	India	Oral	March	30	Saturday	AM	Liver Cirrhosis 06	Prognostic Markers for Improved Survival Estimation in Spontaneous Bacterial Peritonitis (Promise)
102003	Akhil	Deshmukh	India	Oral	March	30	Saturday	AM	Liver Cirrhosis 06	Prognostic Markers for Improved Survival Estimation in Spontaneous Bacterial Peritonitis (Promise)
102008	Ann	Ma	Canada	Oral	March	30	Saturday	AM	Liver Cirrhosis 06	The increasing Burden of Aki and Hrs in Hospitalized Patient with Cirrhosis
102014	Shenoy	K T	India	Oral	March	30	Saturday	AM	Liver Cirrhosis 07	Determinants of Survival in A Large Cohort of Cirrhosis in A Tertiary Care Centre in India
102080	Ning	Han	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 07	Assessing the CaUSAI Association Between Human Blood Metabolites and the Risk of Cirrhosis
200158	Sanal	Mg	India	Oral	March	30	Saturday	AM	Liver Cirrhosis 07	Adipose Tissue Cell Signaling is Dysregulated in Liver Cirrhosis
200188	Ziying	Zhang	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 07	Mesenchymal Stem Cells for the Treatment of Decompensated Cirrhosis (Msc-Dlc-1): A Phase I Trial
200194	Bolormaa	Buuveibaatar	Mongolia	Oral	March	30	Saturday	AM	Liver Cirrhosis 07	The Most Common Etiology, Complication, and Mortality of Lc at the Gastroenterology Center Fchm
200215	Shu	Zhang	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 07	The Efficacy and Safety of Noacs in Cirrhosis and Portal Vein Thrombosis Patients: A Meta-Analysis
100095	Naoki	Hashimoto	Japan	Oral	March	30	Saturday	AM	Liver Cirrhosis 08	Insulin and Glucagon Levels in Relationship with Plasma Amino Acid Imbalance in Liver Cirrhosis
100173	Rui	Huang	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 08	Meld-Sarcopenia Score Predicts Short-Term Readmission of Patients with Hepatic Encephalopathy
100192	Eslam	Habba	Egypt	Oral	March	30	Saturday	AM	Liver Cirrhosis 08	Serum-Ascites Vitamin D Gradient: A Diagnostic Marker for Sbpin Egyptian Cirrhotic Patients
100440	Guofeng	Liu	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 08	Inflammatory Status in Portal Vein is not Associated with the Pvt in Patients with Cirrhosis
100604	Dwijio A	Sindhughosa	Indonesia	Oral	March	30	Saturday	AM	Liver Cirrhosis 08	Npar in Liver Cirrhosis: Novel Prediction Model of 90-Days Mortality and Rehospitalization Risk
100749	Yanna	Liu	China	Oral	March	30	Saturday	AM	Liver Cirrhosis 08	Identifying Small Voices in Patients with Compensated Cirrhosis
100914	Yasuo	Tanaka	Japan	Oral	March	30	Saturday	AM	Liver Cirrhosis 08	Long-Term Efficacy of Rifaximin Treatment in Japanese Patients with Hepatic Encephalopathy
100942	Lorenz Kristoffer	Daga	Philippines	Oral	March	30	Saturday	PM	Liver Cirrhosis 09	Prediction of Mortality in Liver Cirrhosis Patients with Aki Using Nlr, Ctp Score and Infection
101012	Sudhir	Maharshi	India	Oral	March	30	Saturday	PM	Liver Cirrhosis 09	Improvement in Frailty with Nutrition in Patients with Cirrhosis - A Randomized Controlled Trial
101080	Adela	Turcanu	Moldova	Oral	March	30	Saturday	PM	Liver Cirrhosis 09	Poor Monitoring Reduces Survival in Patients with Delta Viral Cirrhosis
101093	Kanwal	Butani	Pakistan	Oral	March	30	Saturday	PM	Liver Cirrhosis 09	Spectrum of Clinical Presentation in Patients with Chronic Liver Disease Secondary to Nafld
101164	Naoki	Hashimoto	Japan	Oral	March	30	Saturday	PM	Liver Cirrhosis 09	Prediction of the Severity of Liver Cirrhosis with Esophageal Varices Determined by Iv-Gtt
101170	Mohammad Mahabub	Rahman	Bangladesh	Oral	March	30	Saturday	PM	Liver Cirrhosis 09	Comparison of Lmr with Cps and Meld Score Determining Severity and Outcome in Cirrhotic Patient
101327	Murk	Mujahid	Pakistan	Oral	March	30	Saturday	PM	Liver Cirrhosis 09	Severity of Liver Cirrhosis is Negatively Correlated to Serum Levels of F13.
101547	Hung	Nguyen	Vietnam	Oral	March	30	Saturday	PM	Liver Cirrhosis 09	Indications of Synchronous Splenectomy for Treatment of HCC with Hypersplenism and Liver Cirrhosis

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
101856	Yangjie	Li	China	Oral	March	30	Saturday	PM	Liver Cirrhosis 10	The Signatures and Interlinks of Gut Bacteria, Fungi and Metabolites in Cirrhotic Patients
101955	Vinod	Arora	India	Oral	March	30	Saturday	PM	Liver Cirrhosis 10	Tolvaptan is Safe and Effective in Management of Hyponatremia in Acute on Chronic Liver Failure
102048	Joshua Vincent H	Baroña	Philippines	Oral	March	30	Saturday	PM	Liver Cirrhosis 10	Clinical Outcomes Among Cirrhotic Patients and their Compliance to Quality Indicators (QI) for Care
200103	Jiarui	Zheng	China	Oral	March	30	Saturday	PM	Liver Cirrhosis 10	Muscle Mass Dynamics is Associated with Long-Term Liver-Related Mortality in Cirrhotic Patients
200132	Naoto	Kawabe	Japan	Oral	March	30	Saturday	PM	Liver Cirrhosis 10	Efficacy and Safety of Long-Term Rifaximin Treatment for Hepatic Encephalopathy
200152	Rajat	Kalra	India	Oral	March	30	Saturday	PM	Liver Cirrhosis 10	Incidence and Associated Risk Factors for Recurrence of Hrs-Aki in Patients with Cirrhosis
100136	Qianqian	Zheng	Japan	Oral	March	30	Saturday	AM	Liver Fibrosis 01	Simultaneous Development of NASH and atherosclerosis in New Zealand and Japanese White Rabbits
100158	Naoshige	ono	Japan	Oral	March	30	Saturday	AM	Liver Fibrosis 01	Interleukin-19 Gene-Deficient Mice Deteriorated Liver Fibrosis Through Tgf-Beta and Ccl2 Signaling
100284	Sasicha	Kitphati	Thailand	Oral	March	30	Saturday	AM	Liver Fibrosis 01	Risk of Liver Fibrosis in Psoriatic Patients with Methotrexate Used: Utility of Noninvasive Approach
100366	Hongcui	Cao	China	Oral	March	30	Saturday	AM	Liver Fibrosis 01	Mscs Alleviate Mouse Liver Fibrosis by Inhibiting Pathogenic Function of Intrahepatic B Cells
100452	Ma. Regina D.	Dimaculangan	Philippines	Oral	March	30	Saturday	AM	Liver Fibrosis 01	Allogeneic Vs Autologous Fecal Microbiota Transplantation Against Liver Fibrosis: A Meta-Analysis
100553	Kazuyoshi	Ohkawa	Japan	Oral	March	30	Saturday	AM	Liver Fibrosis 02	Clinical Verification of Letrozole-Mediated Suppressive Effect on Liver Fibrosis
100579	En-Qiang	Chen	China	Oral	March	30	Saturday	AM	Liver Fibrosis 02	Distribution of Chitinase 3-Like Protein (Ch3L1) in Hbeag-Negative Chb Patients with Normal Alt
100590	Qianwen	Zhao	China	Oral	March	30	Saturday	AM	Liver Fibrosis 02	Translational Potential Role of Zeb2 in Liver Fibrosis and Nafld
100665	Jianhua	Rao	China	Oral	March	30	Saturday	AM	Liver Fibrosis 02	Nogob Promotes Liver Fibrosis by Usp14 Mediated Ripk3-Derived M ¹ Inflammation and Necroptosis
100703	Xiaohao	Wang	China	Oral	March	30	Saturday	AM	Liver Fibrosis 02	Systemic Immune-Inflammation Index Level Negatively Linked with Liver Inflammation and Fibrosis
100825	Minh Duc	Pham	Japan	Oral	March	30	Saturday	AM	Liver Fibrosis 03	Characterize Subpopulations in Liver Fibrosis Derived from Single-Cell Rna Sequencing Analysis
100834	Kutbuddin	Akbary	Singapore	Oral	March	30	Saturday	AM	Liver Fibrosis 03	Fibrosis Distribution in Lean Vs. Obese NASH-Cirrhosis by Shg/Tpe Microscopy
100838	Ruojing	Wang	China	Oral	March	30	Saturday	AM	Liver Fibrosis 03	Androgen Receptor Affects the Proliferation and Metabolism of Hepatic Stellate Cells Through Egfr
100964	Zhengzhao	Lu	China	Oral	March	30	Saturday	AM	Liver Fibrosis 03	Does Timing of Gaining Weight Matter Risk of Non-Alcoholic Fatty Liver Disease Or Liver Fibrosis?
101246	Qin	Ning	China	Oral	March	30	Saturday	AM	Liver Fibrosis 03	Fgl2-C3Ar Mediated Nets Promote Intravascular Coagulation and Liver Fibrosis in NASH Progression
101380	Xiaoning	Wu	China	Oral	March	30	Saturday	AM	Liver Fibrosis 04	Optimal Cut-offs for Diagnosis of Liver Fibrosis in Chronic Hepatitis B During Antiviral Treatment
101997	Victor	Deledinghen	France	Oral	March	30	Saturday	AM	Liver Fibrosis 04	Liverfat Identifies Advanced (Af) Especially Well with Fibroscan in MASLD Patients
102052	Ryo	Yano	Japan	Oral	March	30	Saturday	AM	Liver Fibrosis 04	Deep Attenuation Transducer for Liver Stiffness Measurement in Obese Patients with Liver Disease
200008	Jiayao	Huang	China	Oral	March	30	Saturday	AM	Liver Fibrosis 04	Comparison of 2D-Swe Measurements in Evaluating Liver Fibrosis Using Different Instruments
200145	Ning	Zhang	China	Oral	March	30	Saturday	AM	Liver Fibrosis 04	Crosstalk of Lox and Lox1 Affect Liver Fibrosis Progression Via Notch Pathway
200161	Qi	Han	China	Oral	March	30	Saturday	PM	Liver Fibrosis 05	Ahr Improved Cholestatic Liver Injury by Reducing Neutrophil Infiltration and Modulating Bas Pools
200236	Jiamei	Chen	China	Oral	March	30	Saturday	PM	Liver Fibrosis 05	Total Astragalus Saponins Attenuate Primary Sclerosing Cholangitis in Mice by Upregulation of Tgr5
200237	Jiamei	Chen	China	Oral	March	30	Saturday	PM	Liver Fibrosis 05	Schisantherin A Protects Hepatocyte Via Upregulating Ddah1 to Ameliorate Liver Fibrosis in Mice
200242	Yadong	Fu	China	Oral	March	30	Saturday	PM	Liver Fibrosis 05	Salvianolic Acid B Attenuates Liver Fibrosis by Targeting Ecm1 and Inhibiting Hepatocyte Ferroptosis
100205	Mohamed	Mahboob Ali	Malaysia	Oral	March	30	Saturday	PM	Liver Fibrosis 06	The Role of Vitamin E in the Treatment of Nonalcoholic Steatohepatitis(NASH)
100253	Jan Earl	Lastimoso	Philippines	Oral	March	30	Saturday	PM	Liver Fibrosis 06	Correlation of Hba1C with the Degree of Liver Fibrosis and Steatosis by Fibroscan® in Bacolod City
100881	Wen	Zhang	China	Oral	March	30	Saturday	PM	Liver Fibrosis 06	Magg1 Knockout Inhibits Hepatic Fibrosis Regression by Remodeling Ecm Microenvironment
101250	Dhriti Sundar	Das	India	Oral	March	30	Saturday	PM	Liver Fibrosis 06	Liver Fibrosis Deciphering Clinical Outcomes in Ckd- Brothers in Arms in Prognostic Landscape?
101370	Mengyang	Zhang	China	Oral	March	30	Saturday	PM	Liver Fibrosis 06	Noninvasive Proteomic Biomarkers for Liver Fibrosis Regression in Patients with Chronic Hepatitis B
101557	Manxia	Lin	China	Oral	March	30	Saturday	PM	Liver Fibrosis 06	Predicting Symptomatic Phlf in HCC Patients: Development and Validation of A Preoperative Nomogram
101837	Jialing	Zhou	China	Oral	March	30	Saturday	PM	Liver Fibrosis 07	The Effect of Persistent Decline of Pathological Inflammation on the Regression of Liver Fibrosis
101912	Nurike	Mudjari	Indonesia	Oral	March	30	Saturday	PM	Liver Fibrosis 07	As/Alt Ratio to Predict Hepatic Fibrosis and Steatosis Compared to Fibroscan in Diabetes Patients
101917	Nurike	Mudjari	Indonesia	Oral	March	30	Saturday	PM	Liver Fibrosis 07	Phr Ratio in Predicting Hepatic Steatosis and Fibrosis Compared to Fibroscan in Diabetes Patients
200202	Taylan	Metin	Turkey	Oral	March	30	Saturday	PM	Liver Fibrosis 07	Evaluation of Liver Fibrosis by Fibroscan in Methotrexate Treated Patient
101401	Ian Gabriel	Juyad	Philippines	Oral	March	30	Saturday	PM	Others 01	Efficacy of Rebamipide in the Prevention of Aspirin Or Nsaid-Induced Gastrointestinal Mucosal Injury
101940	Sadam	Bhat	India	Oral	March	30	Saturday	PM	Others 01	Injury to Hepatic Sympathetic Innervation Promotes Liver Injury and Metabolic Dysregulation
101999	MUSArat	Mahtab	Bangladesh	Oral	March	30	Saturday	PM	Others 01	Autologous Haemopoietic Stem Cell Transplantation in Decompensated Cirrhotics Via Portal Venous Route
102051	Joshua Vincent	Baroña	Philippines	Oral	March	30	Saturday	PM	Others 01	Effect of Vonopran on Rebleeding Among Patients with Upper Gi Bleeding: A Meta-Analysis
100301	Qiumin	Luo	China	Oral	March	30	Saturday	PM	Others 02	An In-Hospital HBV Screening Project Improving the Rates of Diagnosis and Treatment of Hepatitis B
100395	Natsuki	tokutake	Japan	Oral	March	30	Saturday	PM	Others 02	Task-Shifting from Doctors to Paramedics for Liver Treatment at Yokkaich Digestive Disease Center
101269	Arka	De	India	Oral	March	30	Saturday	PM	Others 02	Eus-Guided Liver Biopsy and Portal Pressure Gradient Measurement in CaclD and Cirrhosis
101511	Ritwik	Banerjee	India	Oral	March	30	Saturday	PM	Others 02	Rwe Study to Evaluate Effectiveness of Ppis Omeprazole and Pantoprazole for Relief of Gerd/Apd
101879	Takayuki	Kogure	Japan	Oral	March	30	Saturday	PM	Others 02	Spur Cell Anemia Successfully Treated with Liver Transplantation
100289	Yu-Cheng	Lin	Taiwan	Oral	March	30	Saturday	PM	Pediatric Hepatology 01	Gut Microbiome Signatures in Obese Children with Mafld Through Full-Length 16S Rrna Sequencing
100666	Rendi Aji	Prihaningtyas	Indonesia	Oral	March	30	Saturday	PM	Pediatric Hepatology 01	Rct of Methylprednisolone in Cholestasis Infants: Is An Opportunity to Prevent Biliary Atresia?
101149	Nirmala	Deivamani	India	Oral	March	30	Saturday	PM	Pediatric Hepatology 01	Hepatic Lch As Harbinger of Multi-System Lch -Protocol for Diagnosis and Early Prediction
101435	Moinak	Sen Sarma	India	Oral	March	30	Saturday	PM	Pediatric Hepatology 01	Does Intestinal Permeability Impact the Morbidity in Cirrhosis? A Novel Prognostic Model of Outcome
101455	Moinak	Sen Sarma	India	Oral	March	30	Saturday	PM	Pediatric Hepatology 02	Bacterial Translocation in Cirrhosis: Correlation of Jejunal Cultures and Endotoxin Assay
200199	Pragathi	Lk	India	Oral	March	30	Saturday	PM	Pediatric Hepatology 02	Unravelling the Mystery of Cholestatic Liver Disease Using Wes: Unusual Presentation of Pfc 8
200224	Yanwei	Zhong	China	Oral	March	30	Saturday	PM	Pediatric Hepatology 02	Ifitm1 forecast Hbsag Seroconversion in Children with Chb
100197	Fang Kuan	Chiou	Singapore	Oral	March	30	Saturday	PM	Pediatric Hepatology 03	Referral Trends and Real-World Application of Transient Elastography in Pediatric Nafld in Singapore
100396	Arjun	Maria	India	Oral	March	30	Saturday	PM	Pediatric Hepatology 03	Endoscopic Cystogastrotomy in Children with Pancreatic Pseudocyst
100635	Hsin Yu	Chen	Taiwan	Oral	March	30	Saturday	PM	Pediatric Hepatology 03	Predictors for Hypervascular Hepatic Nodules in Patients with Fontan-Associated Liver Disease
101316	Moinak	Sen Sarma	India	Oral	March	30	Saturday	PM	Pediatric Hepatology 03	Galactosemia in Children: Predictors and Risk Factors of Outcome
101332	Moinak	Sen Sarma	India	Oral	March	30	Saturday	PM	Pediatric Hepatology 03	Is Ascites A Risk Factor of Mortality in Pediatric Acute Liver Failure?
101448	Bagus	Setyoboedi	Indonesia	Oral	March	30	Saturday	PM	Pediatric Hepatology 03	Characteristics and Outcomes of Biliary Atresia in A Limited Facility of Liver Transplantation
101497	Iqbal	Taufiqurrachman	Indonesia	Oral	March	30	Saturday	PM	Pediatric Hepatology 03	Hyperinsulinemia Inducing Late Onset Transient Cholestasis in Neonates: A Case Report
101533	Jing	Yang	China	Oral	March	30	Saturday	PM	Pediatric Hepatology 04	Zfyte19 Disease: A Facultative Ciliopathy Initiated by Failure of Cell Division and Cell Death
101985	Nirmala	Deivamani	India	Oral	March	30	Saturday	PM	Pediatric Hepatology 04	Natural History and Renal Involvement of Congenital Hepatic Fibrosis and Caroli Disease
102011	Manasa	Alla	India	Oral	March	30	Saturday	PM	Pediatric Hepatology 04	Pediatric Acute Liver Failure: Experience from A Tertiary Care Center in India
200140	Aabha	Nagral	India	Oral	March	30	Saturday	PM	Pediatric Hepatology 04	Liver Transplantation for Progressive Pediatric Budd Chiari Syndrome
200193	Yanwei	Zhong	China	Oral	March	30	Saturday	PM	Pediatric Hepatology 04	Anti-Hbc Levels Predict Hbsag Seroclearance in Children with Chb
200218	Yanwei	Zhong	China	Oral	March	30	Saturday	PM	Pediatric Hepatology 04	Early Decreased HBV Rna and Hbsag Levels Predicts Treatment Effect in Children with Chb
100065	tomohiro	Tanaka	United States	Oral	March	30	Saturday	AM	Portal Hypertension 01	Assessment of the ApasL Guidance for Albumin Infusion in Therapeutic Paracentesis: Rd Design
100474	Xiaoze	Wang	China	Oral	March	30	Saturday	AM	Portal Hypertension 01	Hepatic Encephalopathy after Tips in Cirrhosis and Sarcopenia: A Systematic Review and Meta-Analysis
100510	Rajesh	Gupta	India	Oral	March	30	Saturday	AM	Portal Hypertension 01	Safety & Efficacy of Endoscopic Glue Vs Eus Guided Coil+Glue in the Treatment of Gastric Varices:Rct
100796	Madhumita	Premkumar	India	Oral	March	30	Saturday	AM	Portal Hypertension 01	Point-of-Care Cardiac Ultrasound(Pocus) Monitoring & Fluid Resuscitation in Cirrhosis with Sepsis
100904	Wei	Gou	China	Oral	March	30	Saturday	AM	Portal Hypertension 01	Reating Diagnostic Models for Liver Cirrhosis Patients with Portal Hypertension Using HvpG
101351	Ankita	Singh	India	Oral	March	30	Saturday	AM	Portal Hypertension 01	Hypersplenism in Non-Cirrhotic Portal Hypertension- Debunking the Spleen'S Guilt
101378	Tanmay	Laxane	India	Oral	March	30	Saturday	AM	Portal Hypertension 02	Clinical Profile of Adolescents Presenting with Portal Hypertension at A Tertiary Care Center
101941	Amit	Agrawal	India	Oral	March	30	Saturday	AM	Portal Hypertension 02	Propofol Sedation in Gastroscopy in Cirrhotics and Utility of Psychometric , Ict Off from Recovery
101991	Rajni	Yadav	India	Oral	March	30	Saturday	AM	Portal Hypertension 02	High-Shear Induced Activation of Piezo1 Develops Portal-Hypertension Via Cytoskeleton Remodelling
102005	Harsh Vardhan	Tevethia	India	Oral	March	30	Saturday	AM	Portal Hypertension 02	Steroid Response in Alcoholic Hepatitis(Ah) Induced Aclf is Based on Severity of Portal Hypertension
102013	Vaibhav	Tiwari	India	Oral	March	30	Saturday	AM	Portal Hypertension 02	Inhibition of Hmgbl Ameliorate Sepsis Induced Lsecs Dysfunction and Portal Hypertension in Cirrhosis
200248	Aniruddha	Singh	India	Oral	March	30	Saturday	AM	Portal Hypertension 02	Comparison of Eus Pv with Intra-Operative Direct Pv Pressure in Pretransplant Cirrhotics-Pilot Study
100227	Ryo	Yano	Japan	Oral	March	30	Saturday	AM	Portal Hypertension 03	Evaluation of Useful Factors for Reclassifying "Unclassified Group" Under Baveno Vii Criteria
100401	Tetsuya	Shimizu	Japan	Oral	March	30	Saturday	AM	Portal Hypertension 03	Clinical Features of Extrahepatic Portal Vein Obstruction: Retrospective Single-Center Study
100439	Guofeng	Liu	China	Oral	March	30	Saturday	AM	Portal Hypertension 03	Outcomes of Cirrhotic Patients with Acute Variceal Bleeding and Concurrent Hepatocellular Carcinoma
100487	Xiaoze	Wang	China	Oral	March	30	Saturday	AM	Portal Hypertension 03	Effect of Time to Tips on Outcomes in Patients with Variceal Bleeding
100524	Jiayin	Wang	China	Oral	March	30	Saturday	AM	Portal Hypertension 03	Shear Wave Dispersion Predicted the High-Risk Egv in Patients with Compensated Cirrhosis
100788	Madhumita	Premkumar	India	Oral	March	30	Saturday	AM	Portal Hypertension 03	Procoagulant Risk & Clinical Outcomes Following Dabigatran Anticoagulation in Portal Vein Thrombosis
100919	Wei	Gou	China	Oral	March	30	Saturday	AM	Portal Hypertension 03	Pay Attention to the Practical Application Value of HvpG in Patients with Liver Cirrhosis
101268	Jiankang	Song	China	Oral	March	30	Saturday	PM	Portal Hypertension 04	Baveno Vii Algorithm to Rule Out Decompensation in Patients with HBV-Related Cirrhosis and Varices
101271	Yuerong	Li	China	Oral	March	30	Saturday	PM	Portal Hypertension 04	The Predictive Value of Hemodynamic Indicators Predict Poor Prognosis after Tips
101273	Min	Wang	China	Oral	March	30	Saturday	PM	Portal Hypertension 04	Spleen Stiffness Measurement Using Mr Elastography for the Noninvasive Assessment of HvpG
101290	Lin	Ma	China	Oral	March	30	Saturday	PM	Portal Hypertension 04	Porto-Sinusoidal Vascular Disease with Risk Factors Had Worse Liver Disease and Poorer Outcomes
101307	Jose Maria	Gonzalez	Philippines	Oral	March	30	Saturday	PM	Portal Hypertension 04	Gallbladder Wall Thickness and Other Non-invasive Tests for the Screening of Esophageal Varices
101521	Xiaofeng	Zhang	China	Oral	March	30	Saturday	PM	Portal Hypertension 04	Combined Baveno Vii-Ssm Model Performed Good to Identify CspH in Individuals with HBV-Related CaclD
101565	Masazumi	onuki	Japan	Oral	March	30	Saturday	PM	Portal Hypertension 05	Outcome of Interventional Radiology for Hepatic Encephalopathy with Port-Systemic Shunt
101868	Hitesh	Singh	India	Oral	March	30	Saturday	PM	Portal Hypertension 05	Correlation of Spleenic and Liver Stiffness Measurement with Variceal Bleeding in NcpH and Cirrhotics
101998	Akhil	Deshmukh	India	Oral	March	30	Saturday	PM	Portal Hypertension 05	Beta-Response: Non-invasive Tests Vs HvpG in Assessing NsbB Response in Acute Variceal Bleed
102084	Rakhi	Maiwall	India	Oral	March	30	Saturday	PM	Portal Hypertension 05	Targeted and Response-Guided Albumin Therapy Improves Outcomes of Ascites in Cirrhosis Patients
102091	Nabila	Elgazzar	Egypt	Oral	March	30	Saturday	PM	Portal Hypertension 05	Carvedilol Versus Band Ligation for Prophylaxis of Variceal Bleeding in Arterial Hypertension Cases
200147	Samridhhi	Poyekar	India	Oral	March	30	Saturday	PM	Portal Hypertension 05	Endovascular Treatment for Acute- Subacute Extensive Splanchnic Venous Thrombosis - A Case Series
100150	Quang Duc	Tran	Vietnam	Oral	March	30	Saturday	PM	Public Health 01	Sbbs Consumption Increases the Risk of Metabolic Syndrome and Its Components in Adults
100241	Hao									

APASL 2024 Kyoto Oral Free Paper Sessions

Submission No.	First Name	Last Name	Country	Style	Month	Date	Day	AM/PM	Session	Abstract Title
101905	Di	Sun	China	Oral	March	30	Saturday	PM	Public Health 03	Prevalence and Risk Factors for Non-Hepatic Cancers in Cirrhosis: A Cross-Sectional Study
200001	Jack	Wallace	Australia	Oral	March	30	Saturday	PM	Public Health 03	Determining the Public Health Implications of Hepatitis B Curative Treatments.
200027	Yasir	Waheed	Pakistan	Oral	March	30	Saturday	PM	Public Health 03	Hepatitis Screening in People Living in Poverty in Pakistan: Step towards Finding Missing Millions
200208	Riska	Astuti	Indonesia	Oral	March	30	Saturday	PM	Public Health 03	Risk of Cigarette Smoking and Liver Disease Based on Demographic Characteristics
100731	Pakanat	Decharatanachart	Thailand	Oral	March	30	Saturday	PM	Public Health 04	Universal Screening for Hepatitis B Infection Before initiating ChemoTherapy is Cost-Effective
100836	Thanh	Kim	Vietnam	Oral	March	30	Saturday	PM	Public Health 04	Effectiveness of Community and Primary Care Models in Promoting HBV Testing for Global Elimination
100967	Pakanat	Decharatanachart	Thailand	Oral	March	30	Saturday	PM	Public Health 04	Cost-Effectiveness of Hepatocellular Carcinoma Surveillance in Viral-Suppressed Chronic Hepatitis B
101013	Lintong	Simbolon	Indonesia	Oral	March	30	Saturday	PM	Public Health 04	How the Caregiver Could increase the QoL of Elderly with Post-Liver Transplantation and Dementia?
101304	Tesfa Sewunet	Alamneh	United Kingdom	Oral	March	30	Saturday	PM	Public Health 04	The Cascade of Care for Hepatitis C Virus Infection Among Adults in Sindh Province, Pakistan
101398	Peter	Vickerman	United Kingdom	Oral	March	30	Saturday	PM	Public Health 04	Impact and Cost-Effectiveness of Scaling Up HCV Treatment Among People Who Inject Drugs in Vietnam
101503	Jalal	Khan	Pakistan	Oral	March	30	Saturday	PM	Public Health 04	Climate Change&Liver Diseases&Impact of Adaptation Strategies to Deal with This Challenge (Pakistan)
101747	Ester Marnita	Purba	Indonesia	Oral	March	30	Saturday	PM	Public Health 05	Early Detection of Liver Disease: How Puskesmas Take Important Role Among 17K islands in Indonesia?
101769	Niyaz	Malayev	Kazakhstan	Oral	March	30	Saturday	PM	Public Health 05	Medical - Social Assessment of the Prevalence of Primary Liver Cancer in Kazakhstan
101831	Jing	Chen	Hong Kong	Oral	March	30	Saturday	PM	Public Health 05	Cost-Effectiveness of Chb Therapy - Implication of New Therapy Vs Expanding the Existing Therapy
101872	Lisa	Hefele	Luxembourg	Oral	March	30	Saturday	PM	Public Health 05	High Exposure to Hepatitis C Virus in Saravan, Laos: Identification of Several Risk Practices
200015	He	Zhao	China	Oral	March	30	Saturday	PM	Public Health 05	Efficacy of Covid-19 Vaccine in Patients with HCC: Analysis of Data from A Prospective Cohort Study
200028	Yasir	Waheed	Pakistan	Oral	March	30	Saturday	PM	Public Health 05	Evaluation of the Performances of Three Rapid Ict Test Being Used for Detection of HCV Antibodies